 Protease Inhibitors
专利摘要:
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is useful for treating diseases in which cysteine proteases, in particular cathepsin K, are inhibitors and in which inhibition of bone loss is effective. <Formula 1> In the above formula, Y is Ar or NR 1 R 2 ; R 1 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O) or R "R'NC (S) ; R 2 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 3 is H, C 2-6 alkenyl, C 2-6 alkynyl, Het, Ar, or OR ', SR', NR ' 2 , N (R) C (O) OR ", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , C 1-6 alkyl optionally substituted by Het or Ar; R 4 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 5 is , Ar-C 0-6 alkyl, Het-C O-6 alkyl, adamantyl-C (O)-, Ar-C (0)-or Het-C (O)-; R 6 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O), R "R'NC (S) or R "OC (O) NR'CH (R * ) C (O); R 7 is C 3-6 cycloalkyl - C O-6 alkyl, Ar-C O-6 alkyl, Het-C O-6 alkyl, Ar-C O-6 alkoxy, Het-C O-6 alkoxy, or OR C, optionally substituted by ', SR ", NR' 2 , N (R ') C (O) OR", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , Het or Ar 1-6 alkyl; R * is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Each R ′ is independently H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "are each independently C 1-6 alkyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "'is H, C 1-6 alkyl, C 3-6 cycloalkyl -C 6 O-alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Z is C (O) or CH 2 ; n is 1, 2 or 3. 公开号:KR20010012316A 申请号:KR1019997010268 申请日:1998-05-06 公开日:2001-02-15 发明作者:로버트 더블유 마르퀴즈；유 루；다니엘 에프. 베버 申请人:스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스；스미스클라인 비참 코포레이션； IPC主号:
专利说明:
Protease Inhibitors Cathepsin K is a member of the enzyme family that is part of the papain superfamily of cysteine proteases. Cathepsins B, H, L, N and S have been described in the literature. Recently, cathepsin K polypeptides and polypeptides encoding cDNAs have been disclosed in US Pat. No. 5,501,969 (called cathepsin C). Cathepsin K has recently been expressed, purified and analyzed (Bossard, M.J. et al., J. Biol. Chem. 271, 12517-15524 (1996); Drake, F. H. et al., J. Biol. Chem. 271, 12511-15516 (1996); Brome, d, et al., J. Biol. Chem. 271, 2126-2132 (1996). Cathepsin K has been indicated variously in the literature, such as cathepsin O, cathepsin X or cathepsin O2. The notation of cathepsin K appears to be more appropriate (named by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology). The catapsin of the papain superfamily of cysteine proteases acts on the general physiological process of proteolysis in animals, including humans, for example, the degradation of connective tissue. However, increased concentrations of these enzymes in the body result in pathological conditions leading to disease. Thus, cathepsin is a variety of infections including pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei and Crithidia fusiculata. Disease conditions as well as schistosomiasis, malaria, tumor metastasis, dysplastic protein disorders, muscular dystrophy, muscular dystrophy and the like have been associated with, but are not limited to. See WO 94/04172, filed March 3, 1995, and the references cited. See also EP 0 603 873 A1 and the references mentioned. blood. Two bacterial cysteine proteases derived from P. gingivallis (called Jinpain) have been implicated in the pathogenesis of gingivitis [Potempa, J. et al. Perspectives in Drug Discovery and Design, 2 , 445-458 (1994). Cathepsin K is believed to be responsible for the disease of excessive loss of bone and cartilage. Bone is composed of a protein matrix incorporating axial- or plate-shaped crystals of hydroxyapatite. Collagen type I is the major structural protein of bone, making up approximately 90% of structural proteins. The remaining 10% of the matrix is a few, including osteocalcin, proteoglycan, osteopontin, osteonectin, thrombospondin, fibronectin, and bone sialoprotein. It is composed of species of non-collagenic proteins. Bones of the skeleton perform remodeling at separate foci throughout their lifetime. These focal points, or remodeling units, perform a circulation consisting of the bone resorption step and subsequent bone replacement. Bone resorption is performed by osteoclasts, which are hematopoietic multinucleated cells. Osteoclasts adhere to the surface of bone to form a tight hermetic zone and excessive membrane wrinkles on its top surface (ie, reabsorption). This creates an extracellular compartment surrounded on the bone surface that is acidified by a proton pump in the corrugated membrane, into which the osteoclasts secrete proteolytic enzymes. The low pH of the compartment dissolves hydroxyapatite crystals at the surface of the bone and the proteolytic enzyme digests the protein matrix. In this way, resorption tears or holes are formed. At the end of this cycle, the osteoclasts store a new protein matrix, which is mineralized. In several disease symptoms, such as osteoporosis and Paget's disease, the general balance between bone resorption and formation is impaired, resulting in a net loss of bone in each circulation. As a result, it causes bone weakness and allows for increased risk of fracture with minimal impact. Abundant selective expression of cathepsin K in osteoclasts strongly suggests that this enzyme is essential for bone resorption. Thus, selective inhibition of cathepsin K provides an effective treatment for excessive loss of bone diseases, including but not limited to osteoporosis, gingival diseases (gingivitis and periodontitis), Farget's disease, hypercalcemia of malignancies and metabolic diseases do. In addition, the concentration of cathepsin K has been described to be increased in the chondrocytes of the osteoarticular periosteum. Thus, inhibition of cathepsin K may also be useful for treating excessive degradation diseases of the cartilage or matrix, including but not limited to osteoarthritis and rheumatoid arthritis. Metastatic tumor cells also typically express high concentrations of proteolytic enzymes that degrade the surrounding matrix. Thus, selective inhibition of cathepsin K may also be useful for the treatment of certain neoplastic diseases. It is now found that new species of compounds are protease inhibitors, most particularly inhibitors of cathepsin K, and that these compounds are useful for the treatment of diseases requiring inhibition of bone resorption, such as osteoporosis and periodontal disease. Summary of the Invention It is an object of the present invention to further more specifically, such as compounds which inhibit the cysteine protease of papain superfamily, more particularly such compounds which inhibit cysteine protease, such as inhibitors of protease inhibitors, in particular cysteine and serine proteases. In particular, it is to provide compounds useful for the treatment of diseases that can be improved therapeutically by inhibiting cathepsin K and replacing the activity of such proteases most specifically, such as compounds that inhibit the cysteine proteases of the cathepsin family. Thus, in a first aspect the present invention provides a compound of formula (I). In another aspect the invention provides a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier. In addition, in another aspect, the present invention relates to a protease, in particular cysteine and serine protease, more specifically cysteine protease, more specifically papain superfamily of cysteine proteases, more specifically, the cysteine protease of the cathepsin family, Most specifically, the present invention provides a method of treating a disease that can be improved therapeutically by inhibiting cathepsin K. In a specific aspect, the compounds of the present invention are particularly useful for treating bone loss such as osteoporosis and gingival diseases (gingivitis, periodontitis) or diseases characterized by excessive degradation of cartilage or matrix such as osteoarthritis and rheumatoid arthritis. The present invention relates to novel protease inhibitors, in particular inhibitors of cysteine and serine proteases, more specifically compounds that inhibit cysteine proteases, and more particularly compounds that inhibit cysteine proteases of papain superfamily, more specifically cysteines of the cathepsin family Compounds that inhibit proteases, most particularly compounds that inhibit cathepsin K. Such compounds are particularly useful for treating cysteine proteases, in particular excessive loss of bone or cartilage, such as diseases of osteoporosis, periodontitis and arthritis. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof. In the above formula, Y is Ar or NR 1 R 2 ; R 1 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O) or R "R'NC (S) ; R 2 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 3 is H, C 2-6 alkenyl, C 2-6 alkynyl, Het, Ar, or OR ', SR', NR ' 2 , N (R) C (O) OR ", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , C 1-6 alkyl optionally substituted by Het or Ar; R 4 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 5 is , Ar-C 0-6 alkyl, Het-C O-6 alkyl, adamantyl-C (O)-, Ar-C (0)-or Het-C (O)-; R 6 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O), R "R'NC (S) or R "OC (O) NR'CH (R * ) C (O); R 7 is C 3-6 cycloalkyl - C O-6 alkyl, Ar-C O-6 alkyl, Het-C O-6 alkyl, Ar-C O-6 alkoxy, Het-C O-6 alkoxy, or OR C, optionally substituted by ', SR ", NR' 2 , N (R ') C (O) OR", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , Het or Ar 1-6 alkyl; R * is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Each R ′ is independently H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "are each independently C 1-6 alkyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "'is H, C 1-6 alkyl, C 3-6 cycloalkyl -C 6 O-alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Z is C (O) or CH 2 ; n is 1, 2 or 3. Preferably, the present invention provides a compound of formula (la) or a pharmaceutically acceptable salt thereof. In the above formula, R 1 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O) or R "R'NC (S) ; R 2 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 3 is H, C 2-6 alkenyl, C 2-6 alkynyl, Het, Ar, or OR ', SR', NR ' 2 , N (R) C (O) OR ", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , C 1-6 alkyl optionally substituted by Het or Ar; R 4 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 5 is , Ar-C 0-6 alkyl, Het-C O-6 alkyl, adamantyl-C (O)-, Ar-C (0)-or Het-C (O)-; R 6 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O), R "R'NC (S) or R "OC (O) NR'CH (R * ) C (O); R 7 is C 3-6 cycloalkyl - C O-6 alkyl, Ar-C O-6 alkyl, Het-C O-6 alkyl, Ar-C O-6 alkoxy, Het-C O-6 alkoxy, or OR C, optionally substituted by ', SR ", NR' 2 , N (R ') C (O) OR", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , Het or Ar 1-6 alkyl; R * is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Each R ′ is independently H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "are each independently C 1-6 alkyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "'is H, C 1-6 alkyl, C 3-6 cycloalkyl -C 6 O-alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Z is C (O) or CH 2 ; n is 1, 2 or 3. The present invention includes all hydrates, solvates, complexes and drug precursors of the compounds of the present invention. The drug precursor is any covalently bound compound that releases the active parent drug according to formula (I) in vivo. Where other forms of chiral or isomeric centers are present in the compounds of the invention, all forms of such isomers or isomers (including enantiomers and diastereomers) are included herein. Compounds of the invention comprising chiral centers may be used as racemic mixtures, enantiomer-rich mixtures, or racemic mixtures may be separated using known techniques, and individual enantiomers may be used alone. If the compound comprises an unsaturated carbon double bond, both the cis (Z) and trans (E) isomers are within the scope of the present invention. When the compound is present in the form of a tautomer, such as a keto-inol tautomer, each tautomeric form is present in equilibrium or in one form prevailing or is considered to be included in the present invention. The meaning of any substituent at any occurrence of Formula (I) or any subformulae thereof is irrelevant to its meaning or, unless otherwise indicated, the meaning of any other substituent at any one occurrence of Irrelevant According to formula (I): Suitably, R 4 and R ″ ′ are each H and R 3 is C 1-6 alkyl or C 2-6 alkyl. Preferably, R 3 is i-butyl. Suitably, R 5 is benzyl or picture, (Wherein R 'is H, R 7 is C 1-6 alkyl, preferably i-butyl, R 6 is R "OC (O), R" is benzyl and Z is CH 2 ) Suitably, Y is NR 1 R 2 , R 2 is H and R 1 is R ″ C (O) or R ″ OC (O), where R ″ is C 1-6 alkyl, Ar—C 0- 6 alkyl or Het-C 0-6 alkyl, most preferably R " is tert-butyl, Im). Suitably n is 1 or 2. Preferably n is 1. In one particular embodiment, the compound of formula (la) of the invention is a compound of formula (lb). In another embodiment, the compound of formula (Ia) of the present invention is a compound of formula (Ic): Specific representative compounds of the present invention and pharmaceutically acceptable salts thereof are as follows. 3-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pi Lollidine; 1-benzyl-3-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino]-pyrrolidine; 3-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl]- Pyrrolidine; 1-benzyl-3-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (benzyloxycarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucinyl] amino] -pyrrolidine; (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3R)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; 1-benzyl- (3R)-[[N α- (2-naphthyl) acetyl-L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3R)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3R)-[[N α- (3-quinolinecarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3R)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3R)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (2-naphthyl) acetyl-L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (3-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl-4-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -piperidine; 1-benzyl-4-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -piperidine; 1-benzyl-4-[[N α- (benzyloxycarbonyl) -L-leucineyl] amino] -piperidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (1-adamantanecarbonyl)-(3R)-[[N α- (4-pyridylmethoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (1-adamantanecarbonyl)-(3S)-[[N α- (4-pyridylmethoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; (3R)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Carbonyl) amino] pentyl] -pyrrolidine; (3R)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3R)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3R)-[[N α- (benzothiazole-6-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine; (3R)-[[N α- (indol-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3R)-[[N α- (4-fluorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -Pyrrolidine; (3R)-[[N α- (4-methoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -Pyrrolidine; (3R)-[[N α- (3,4-dichlorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3R)-[[N α- (thiophen-2-carbonyl) -L-leucineyl] amino] -1-((2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3R)-[[N α- (4-biphenylcarbonyl) -L-leucineyl] amino] -1-((2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3R)-[[N α- (5-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbine Carbonyl) amino] pentyl] -pyrrolidine; (3R)-[[N α- (5-chlorobenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl ) Amino] pentyl] -pyrrolidine; (3R)-[[N α- (7-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Carbonyl) amino] pentyl] -pyrrolidine; (3R)-[[N α- (3-chlorobenzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[( Benzyloxycarbonyl) amino] pentyl] -pyrrolidine; (3R)-[[N α- (3- (2-pyridyl) benzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) Amino] pentyl] -pyrrolidine; (3S)-[[N α- (benzo [b] thiophene-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbine Carbonyl) amino] pentyl] -pyrrolidine; (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3S)-[[N α- (benzothiazole-6-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine; (3S)-[[N α- (indol-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3S)-[[N α- (4-fluorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -Pyrrolidine; (3S)-[[N α- (4-methoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -Pyrrolidine; (3S)-[[N α- (3,4-dichlorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3S)-[[N α- (thiophene-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3S)-[[N α- (4-biphenylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3S)-[[N α- (5-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Carbonyl) amino] pentyl] -pyrrolidine; (3S)-[[N α- (5-chlorobenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl ) Amino] pentyl] -pyrrolidine; (3S)-[[N α- (7-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Carbonyl) amino] pentyl] -pyrrolidine; (3S)-[[N α- (3-chlorobenzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[( Benzyloxycarbonyl) amino] pentyl] -pyrrolidine; (3S)-[[N α- (3- (2-pyridyl) benzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) Amino] pentyl] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (benzyloxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (3-chlorobenzo [b] thiophen-2-carbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-fluoro) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-fluoro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-fluoro) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-cyano) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-cyano) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (3- (2-dimethylaminoethoxy) -4-methoxybenzoyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4- (N, N-dimethylamino) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-methoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-carboxymethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3,4-methylenedioxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-naphthyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-Indolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-quinolinyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-quinolinyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (1-naphthyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-quinolinyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-pyrrolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (3-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-acetamido) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-cyano) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-fluoro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-phenoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-chloro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-Trifluoromethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-trifluoromethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4- (3- (N, N-dimethylamino) propoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine ; 1- (4- (isopropyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-benzofuranyl) methyl- (3S)-[[N α- (2-leucineyl) naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2- (3-methylbenzo [b] thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3,4-dimethoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; or 1- (5-Nitro-3-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine. In still another embodiment, the present invention provides novel intermediates useful for the preparation of compounds of formula (I) represented by formula (II) or pharmaceutically acceptable salts thereof. In the above formula, R 3 is H, C 2-6 alkenyl, C 2-6 alkynyl, Het, Ar, or OR ', SR', NR ' 2 , N (R) C (O) OR ", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , C 1-6 alkyl optionally substituted by Het or Ar; R 4 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 5 is , Ar-C 0-6 alkyl, Het-C O-6 alkyl, adamantyl-C (O)-, Ar-C (0)-or Het-C (O)-; R 6 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O), R "R'NC (S) or R "OC (O) NR'CH (R * ) C (O); R 7 is C 3-6 cycloalkyl - C O-6 alkyl, Ar-C O-6 alkyl, Het-C O-6 alkyl, Ar-C O-6 alkoxy, Het-C O-6 alkoxy, or OR C, optionally substituted by ', SR ", NR' 2 , N (R ') C (O) OR", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , Het or Ar 1-6 alkyl; R * is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Each R ′ is independently H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "are each independently C 1-6 alkyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "'is H, C 1-6 alkyl, C 3-6 cycloalkyl -C 6 O-alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Z is C (O) or CH 2 ; n is 1, 2 or 3. Abbreviations and symbols commonly used in the field of peptides and chemicals are used herein to describe the compounds of the present invention. Generally, such amino acid abbreviations are described in Eur. J. Biochem., 158, 9 (1984), follow the IUPAC-IUB Joint Conference on Biochemical Nomenclature. The term "amino acid" as used herein refers to alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine Means D- or L-isomer. As used herein, “C 1-6 alkyl” refers to substituted and unsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, pentyl, n-pentyl, isopentyl, Neopentyl and hexyl and their simple aliphatic isomers. Any C 1-6 alkyl group is one or two halogen, SR ', OR', N (R ') 2 , C (O) N (R') 2 , carbamyl or C 1-4 alkyl, wherein , R 'is H or C 1-6 alkyl. C 0 alkyl means that no alkyl is present in some. Thus, Ar-C 0 alkyl is the same as Ar. As used herein, "C 3-6 cycloalkyl" is meant to include substituted and unsubstituted cyclopropane, cyclobutane, cyclopentane and cyclohexane. As used herein, "C 2-6 alkenyl" refers to an alkyl group of 2 to 6 carbons in which a carbon single bond is replaced with a carbon double bond. C 2-6 alkenyl includes ethylene, 1-propene, 2-propene, 1-butene, 2-butene, isobutene and various pentene and hexene isomers. Both cis and trans isomers are included. As used herein, "C 2-6 alkynyl" refers to an alkyl group of 2 to 6 carbons in which a carbon single bond is replaced with a carbon double bond. C 2-6 alkynyl includes simple isomers of acetylene, 1-propyne, 2-propyne, 1-butyne, 2-butyne, 3-butyne and fentin and hexin. "Halogen" or "halo" means F, Cl, Br and I. "Ar" or "aryl" means unsubstituted phenyl or naphthyl; Or at least one Ph-C 0-6 alkyl, Het-C 0-6 alkyl, C 1-6 alkoxy, Ph-C 0-6 alkoxy, Het-C 0-6 alkoxy, OH, (CH 2 ) 1- Phenyl or naphthyl substituted by 6 NR'R ', O (CH 2 ) 1-6 NR'R', wherein each R 'is independently H, C 1-6 alkyl, Ar-C 0-6 alkyl Or Het-C 0-6 alkyl; Or 1 to 4 selected from C 1-4 alkyl, OR ', N (R') 2 , SR ', CF 3 , NO 2 , CN, CO 2 R', CON (R '), F, Cl, Br and I Means phenyl or naphthyl substituted with three moieties or substituted with methylene dioxy groups. As used herein, "Het" or "heteroaryl" is a stable 5-7 membered monocyclic or stable 7-10 membered bicyclic heterocyclic ring, which is substituted or unsubstituted, and is substituted with 1 carbon atom. And heteroatoms selected from the group consisting of 4 N, O or S, wherein double nitrogen and sulfur may be optionally oxidized, the nitrogen atom may be optionally quaternized, any of the heterocyclic rings defined above And bicyclic groups fused to benzene rings. The heterocyclic ring may be attached to any hetero atom or carbon forming a stable structure, and C 1-4 alkyl, OR ', N (R') 2 , SR ', CF 3 , NO 2 , CN, CO May be optionally substituted with one or two types selected from 2 R ′, CON (R ′), F, Cl, Br and I, wherein R ′ is as defined above. Examples of such heterocyclic compounds include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazapineyl, azepineyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridyl, pyrazinyl, oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, Thiazolinyl, thiazolyl, quinuclidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, benzoxazolyl, furyl, pyranyl, tetrahydrofuryl, tetrahydropyranyl, Thienyl, thiamopolyyl sulfoxide, thiamopolyyl sulfone, oxadiazolyl, benzothiazolyl, benzoisothiazolyl, benzoisoxazolyl, pyrimidinyl, cinnolinyl, quinazolinyl, quinoxazolinyl, 1,5-naphthyridinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, tetrazolyl, 1,2,3- Ria include thiazolyl and 1,2,4-triazolyl. "Het" also has aromatic properties, i.e. pyridinyl, quinolinyl, isoquinolinyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl , Indolyl, benzimidazolyl, benzoxazolyl, furyl, thienyl, oxadiazolyl, benzothiazolyl, benzoisothiazolyl, benzisoxazolyl, pyrimidinyl, cinnaolinyl, quinazolinyl, quinoxalinyl , 1,5-naphthyridinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, tetrazolyl, 1,2,3-triazolyl and 1,2,4 -Triazolyl means any heterocyclic moiety included in the definition of Het. Certain radical groups are abbreviated herein. t-Bu means quaternary butyl radical, Boc or BOC is t-butoxycarbonyl radical, Fmoc is fluorenylmethoxycarbonyl radical, Ph is phenyl radical, Cbz or CBZ is benzyloxycarbonyl radical. Certain reagents are abbreviated herein. DCC means dicyclohexylcarbodiimide, DMAP means 2,6-dimethylaminopyridine, EDC or EDCI means N-ethyl-N '(dimethylaminopropyl) -carbodiimide. HOBT or HOBt is 1-hydroxybenzotriazole, DMF is dimethyl formamide, BOP is benzotriazol-1-yloxy-tris (dimethylamino) phosphonium hexafluorophosphate, DIEA is di-isopropylethylamine, Lawson's reagent is 2,4-bis (4-methoxyphenyl) -1,3-dithia-2,4-diphosphetane-2,4-disulfide, NMM is N-methylmorpholinine, TFA is tri Fluoroacetic acid, TFAA means trifluoroacetic anhydride, KHMDS means potassium hexamethyldisilazide and THF means dihydrofuran. Jones' reagent is a solution of chromium dioxide, water and sulfuric acid, well known in the art. Compounds of formula (I) generally refer to compounds of formula (II) or salts thereof in which the reactive functional groups are protected, (a) reacts with R ″ C (O) Cl; (b) react with R ″ C (O) OH in the presence of EDC and HOBT; (c) react with R ″ C (O) H and then reduce; (d) react with R ″ CO (O) Cl in the presence of a base; (e) after reacting with R ″ SO 2 Cl in the presence of a base; By removing any protecting group and optionally forming a pharmaceutically acceptable salt. <Formula II> Wherein R ″, R 3 , R 4 , R 5 and n are as defined in formula (I). Compounds of formula (I) are prepared by the same method as described in Schemes 1 and 2. Compounds of general formula (I) wherein n is 1, R 5 is an alkyl group and R 1 is R'C (O) can be prepared as shown in Scheme 1. Commercially available amines (1 in Scheme 1, which can be racemic or enantiomericly pure forms), are aldehyde-reducible alkylations such as benzaldehyde or CBZ-leucine, followed by reducing agents such as sodium triacetoxyborohydride. And quaternary amine (2 in Scheme 1) is obtained. 2 in Scheme 1 is treated with ethyl acetate or a strong acid such as hydrochloric acid in ether or dioxane and methanol to remove the protecting group, yielding 3 in Scheme 1. Scheme 1 3 may be coupled with an acid using EDC and HOBT in an aprotic solvent such as dichloromethane in the presence of a base such as N-methylmorpholine or triethylamine to obtain 4 of Scheme 1. The protecting groups of 4 of Scheme 1 can be removed with strong acids such as hydrochloric acid in ethyl acetate or ether or dioxane and methanol to afford 5 of Scheme 1. Coupling of the amine salt (5 in Scheme 1) is possible using an acid in the presence of a base such as EDC, HOBt and N-methylmorpholine, yielding 6 in Scheme 1. The salts (5 in Scheme 1) can also be converted to sulfonamide derivatives by treatment with sulfonyl chloride in an aprotic solvent such as dichloromethane in the presence of a base such as triethylamine. Compounds of general formula (I) wherein n is 2, R 5 is a benzyl group and R 1 is R'C (O) can be prepared as shown in Scheme 1. Commercially available 4-amino-1-benzylpiperidine (1 in Scheme 1) was acylated with N-BOC-leucine in dichloromethane in the presence of EDC, HOBT and N-methylmorpholine to obtain Scheme 2 (2). Scheme 2 was obtained by removing the protecting group with ethyl acetate or ether or dioxane and methanol with anhydrous hydrochloric acid. Amine salt Scheme 2 3 is acylated with the carboxylic acid described above to obtain 4 of Scheme 2. Starting materials used herein are commercially available amino acids or prepared by general methods well known to the person skilled in the art and described in COMPENDIUM OF ORGANIC SYNTHETIC METHODS, Vol. It can be found in standard reference books such as I-VI (Wiley-Interscience Publishing). Coupling methods for forming amide bonds herein are generally well known in the art. Peptide synthesis methods are generally described by Bodansky et al. [THE PRACTICE OF PEPTIDE SYNTHESIS, Springer-Verlag, Berlin, 1984], E. Gross and J. Meienhofer [THE PEPTIDES, Vol. 1, 1-284 (1979) and in JM Stewart and JD Young, SOLID PHASE PEPTIDE SYNTHESIS, 2d Ed., Pierce Chemical Co., Rockford, Ill., 1984, It is generally an example of the present technology and is incorporated herein by reference. Synthetic methods for preparing compounds of the present invention often use protecting groups to mask reactive functional groups or to minimize unwanted side reactions. Such protecting groups are generally described in Green, T.W., PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, New York (1981). The term "amino protecting group" generally refers to the Boc, acetyl, benzoyl, Fmoc and Cbz groups and derivatives thereof, as known in the art. It is well known to protect and deprotect, and to replace amino protecting groups with another moiety. Acid addition salts of compounds of formula (I) are suitable solvents from the parent compound and from excess acids such as hydrochloric acid, bromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid or methanesulfonic acid It is prepared by standard methods. Certain compounds form acceptable internal salts or zwitterions. Cationic salts are prepared by treating the parent compound with an excess of alkaline reagents comprising a suitable cation such as hydroxide, carbonate or alkoxide or with a suitable organic amine. Cations such as Li + , Na + , K + , Ca ++ , Mg ++ and NH 4+ are specific examples of cations that may be present in pharmaceutically acceptable salts. Halides, sulfates, phosphates, alkanoates (such as acetates and trifluoroacetates), benzoates and sulfonates (such as mesylates) are specific examples of anions that may be present in pharmaceutically acceptable salts. The present invention also provides a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, diluent or excipient. Thus, the compounds of formula (I) can be used for the preparation of a medicament. Pharmaceutical compositions of the compounds of formula (I) prepared as described above may be formulated in lyophilized powder for solution or parenteral administration. The powder can be returned to its original state by the use of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation may be a buffered, isotonic aqueous solution. Examples of suitable diluents are normal isotonic saline, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulations are particularly suitable for parenteral administration, but may be used for oral administration or stored in metered dose inhalers or inhalational nebulizers. It may also be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate. Alternatively, such compounds may be prepared in encapsulated, tableted or emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition or to facilitate the preparation of the composition. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. Liquid carriers include syrup, peanut oil, olive oil, saline and water. Carriers also include those sustained release materials such as glycerin monostearate or glyceryl distearate alone or in combination with waxes. The amount of solid carrier varies but is preferably about 20 mg to about 1 g per titration amount. Pharmaceutical formulations are prepared according to conventional pharmaceutical techniques such as in the form of tablets which are ground, mixed, granulated and compressed if necessary or in the form of hard gelatin capsules which are mixed and filled. If a liquid carrier is used, the preparation is in the form of a syrup, elixir, emulsion or aqueous or non-aqueous suspension. Such liquid formulations may be administered orally directly or filled into soft gelatin capsules. For rectal administration, the compounds of the present invention may also be formulated into suppositories in combination with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycol. Compounds of formula (I) are protease inhibitors, in particular inhibitors of cysteine and serine proteases, more specifically inhibitors of cysteine proteases, more specifically inhibitors of cysteine proteases of papain superfamily, and more specifically cysteine proteases of the cathepsin family It is useful as an inhibitor of, most particularly as an inhibitor of cathepsin K. The present invention also provides useful compositions and formulations of the compounds, including pharmaceutical compositions and formulations of the compounds. The present compounds include infections with pneumocytosis, malaria, tumor metastasis, as well as those with infections by pneumocytis carini, trysanoma cruise, trypsanoma brusei and cryiddia fuzikulata, involving cysteine proteases. Diseases such as dystonia, muscular dystrophy, muscular dystrophy and cathepsin K, most particularly associated with excessive loss of bone or cartilage, osteoporosis, gingivitis and gingivitis, arthritis, more specifically osteoarthritis and rheumatoid arthritis, It is useful for the treatment of diseases such as diseases and malignant tumors and metabolic bone diseases. Metastatic tumor cells also typically express high concentrations of proteolytic enzymes that degrade the surrounding matrix, and certain tumors and metastatic tumors can be effectively treated using the compounds of the present invention. The invention also relates to the pathological concentrations of proteases, in particular cysteine and serine proteases, more specifically cysteine proteases, more specifically inhibitors of cysteine proteases of papain superfamily, more particularly inhibitors of cysteine proteases of the cathepsin family. Provided are methods for the treatment of the resulting disease, which method comprises administering a compound of the invention to an animal, in particular a mammal, most particularly a person in need thereof. The present invention provides a method for the treatment of diseases caused by pathological concentrations of cathepsin K, in particular cathepsin comprising the compounds of the present invention in animals, in particular mammals, and most particularly those in need thereof. Administering an inhibitor of K. The present invention particularly provides a method for the treatment of a disease involving cysteine proteases, including not only infections by pneumocytis carini, trypsinoma cruji, trypsinoma brusei and cryiddia fuzikulata Diseases such as schistosomiasis, malaria, tumor metastasis, otitis leukoplasty, muscular dystrophy, muscular dystrophy and cathepsin K, most particularly associated with excessive loss of bone or cartilage, gingivitis, including osteoporosis, gingivitis and periodontitis Specifically, diseases such as osteoarthritis and rheumatoid arthritis, Farget's disease, and malignant tumors and metabolic bone diseases are included. The present invention also relates to treating osteoporosis or administering to a patient an effective amount of a compound of formula (I) alone or in combination with bisphosphonates (i.e., allandronate), hormone replacement therapy, other bone resorption inhibitors such as anti-estrogen or calcitonin. It provides a method for inhibiting bone loss, including. In addition, treatments using compounds of the invention and anabolic agents such as bone morphogenic proteins, iproflavones, can be used to inhibit bone loss or increase bone weight. Parenteral administration of the compound of formula (I) is preferred for acute treatment. Although intramuscular mass injection is also useful, it is most effective to inject the compound intravenously with 5% dextrose in a similar formulation with water or normal saline or a suitable excipient. Typically, the parenteral dose is about 0.01 to about 100 mg / kg, and preferably maintains the concentration of drug in the plasma at a concentration effective to inhibit cathepsin K, which is preferably 0.1 to 20 mg / kg. The compound is administered 1 to 4 times daily at a concentration that can achieve a total daily dose of about 0.4 to 400 mg / kg / day. The exact amount of a therapeutically effective compound of the present invention and the route by which such compound is best administered is readily determined by the person skilled in the art by comparing the blood concentration of the agent with the concentration necessary to produce a therapeutic effect. The compounds of the invention can also be administered orally to a patient so that the concentration of the drug is sufficient to inhibit bone resorption or to achieve any other therapeutic indication as described herein. Typically, pharmaceutical compositions comprising a compound are administered at an oral dosage of about 0.1 to about 50 mg / kg, consistent with the condition of the patient. Preferably the oral dosage is about 0.5 to about 20 mg / kg. No unacceptable toxic effects are expected when the compounds of the present invention are administered in accordance with the present invention. Compounds of the invention can be tested in one of several biological assays to determine the concentration of compounds required to produce a given pharmacological effect. Measurement of Proteolytic Catalytic Activity of Cathepsin K All assays for cathepsin K were performed using human recombinant enzyme. Standard assay conditions for determination of reaction rate constants were determined using a fluorogenic peptide substrate, typically Cbz-Phe-Arg-AMC, at 100 mM sodium acetate, pH 5.5, containing 20 mM cysteine and 5 mM EDTA. Stock substrate solution was prepared to a final substrate concentration of 20 μM in the analyte at a concentration of 10 or 20 mM in DMSO. All analytes contained 10% DMSO. Independent experiments revealed that this concentration of DMSO had no effect on enzyme activity or reaction rate constants. All analyzes were performed at ambient temperature. The fluorescence of the product (360 nM excitation; 460 nM emission) was measured with a Perceptive Biosystems Cytofluor II fluorescent plate reader. Progress curve of the product was generated for 20-30 minutes after AMC product formation. Inhibition studies Probable inhibitors were evaluated using the progress curve method. Assays were performed in the presence of various concentrations of test compounds. The reaction was initiated by adding the enzyme to a buffered solution of inhibitor and substrate. Data analysis was performed according to one of two methods depending on the appearance of the progress curve in the presence of the inhibitor. For compounds with linear progression curves, the apparent inhibition constant (K i, app ) was calculated according to Equation 1 (see Brandt et al., Biochemistry, 1989, 28, 140). v = V m A / [K a (I + I / K i, app ) + A] Where v is the reaction rate with the highest rate of Vm, A is the concentration of substrate with Michaelis constant Ka and I is the concentration of inhibitor. For compounds with downward curvature whose progression curves are characterized by time dependent inhibition, the data from the individual sets are analyzed to obtain k obs according to equation (2). [AMC] = v ss t + (v0-v ss ) [I-exp (-k obs t)] / k obs Where [AMC] is the concentration of product formed over time t, v0 is the initial reaction rate and v ss is the final steady state rate. Values for k obs were analyzed as a linear function of inhibitor concentration to produce an apparent second order rate constant (k obs / inhibitor concentration or k obs / [I]) indicating time dependent inhibition. A complete discussion of such kinetics treatments can be found in Morrison et al., Adv. Enzymol. Relat. Areas Mol. Biol., 1988, 61,201. Those skilled in the art will recognize that any compound with a K i of less than 50 mM will be a likely main compound. Preferably, the compound used in the method of the present invention has a K i value of less than 1 mM. Most preferably the compound has a K i value of less than 100 nM. 4- (R, S) -amino-N-[(8-quinolinsulfonyl) -S-leucine] -3-tetrahydrofuran-3-one, a compound of formula (I), has a K i greater than 10 mM Has a value. Human osteoclast resorption analysis A aliquot of the cell suspension derived from osteoclasts was removed from the liquid nitrogen reservoir, heated rapidly to 37 ° C. and washed once with RPMI-1640 medium by centrifugation (1000 rpm, 5 min at 4 ° C.). The medium was aspirated and replaced with murine anti-HLA-DR antibody, diluted 1: 3 in RPMI-1640 medium and incubated for 30 minutes on ice. Cell suspensions were often mixed. The cells were washed twice with RPMI-1640 medium cooled by centrifugation (1000 rpm, 5 min at 4 ° C.) and then transferred to sterile 15 ml centrifuge tubes. The number of monocytes was counted in the improved Neubauer counting chamber. Sufficient magnetic beads (5 / monocytes) coated with goat anti-mouse IgG were removed from their storage container and placed in 5 ml of fresh medium (washed with toxic azide preservative). The beads were fixed on the magnet to remove the medium and replaced with a new medium. Beads were mixed with cells and the suspension was incubated for 30 minutes on ice. The suspension is often mixed. Bead-coated cells were immobilized on magnets and the remaining cells (fractions rich in osteoclasts) were removed in sterile 50 ml centrifuge tubes. Fresh media was added to the bead-coated cells and the trapped osteoclasts were removed. This washing process was repeated 10 times. Bead-coated cells were removed. Osteoclasts were counted in a counting chamber filled with samples using a disposable plastic Pasteur pipette with a large internal diameter. The cells were pelleted by centrifugation and the density of osteoclasts was adjusted to 1.5 × 10 4 / ml in EMEM medium and supplemented with 10% fetal calf serum and 1.7 g / l sodium bicarbonate. Aliquots of 3 ml of cell suspension were subtracted into 15 ml centrifuge tubes. These cells were pelleted by centrifugation. 3 ml of appropriate treatment was added to each tube (diluted to 50 μM in EMEM medium). Also included were appropriate vehicle standards, positive standards (diluted 87MEM1 to 100 μg / ml) and same reference sample standards (diluted IgG2a to 100 μg / ml). The tube was incubated at 37 ° C. for 30 minutes. Aliquots of 0.5 ml of cells were seeded in thin slices of sterile dentin in 48-well plates and incubated at 37 ° C. for 2 hours. Each treatment was covered in four layers. The flakes were washed six times with heated PBS (10 ml / well in a six-well plate) and then placed in a new therapeutic or standard and incubated at 37 ° C. for 48 hours. Thin slices were washed with phosphate buffered saline and fixed with 2% glutaaldehyde (in 0.2 M sodium cacodylate) for 5 minutes, then washed with water and incubated at 37 ° C. for 5 minutes in buffer. The flakes were washed with cold water and incubated for 5 minutes at 4 ° C. in cooled acetate buffer / solid red garnet. Excess buffer was aspirated off and the flakes were washed with water and dried in air. TRAP positive osteoclasts were counted by bright field microscopy and removed from the dentin surface using ultrasound. Pore volume was measured using a Nikon / Lasertec ILM21W confocal microscope. Nuclear magnetic resonance spectra were recorded using a Bruker AM 250 or Bruker AC 400 spectrometer individually at 250 or 400 MHz. CDCl 3 is deuterochloroform, DNSO-d 6 is hexadeuteriodimethylsulfoxide and CD 3 OD is tetradeuteriomethanol. Chemical shifts are reported in ppm (d) downfield from internal standard tetramethylsilane. Abbreviations for NMR data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet among doublets, dt = doublet among triplets, app = Clear, br = spread. J is the NMR coupling constant measured in Hetz. Continuous wave infrared (IR) spectra were recorded on a Perkin-Elmer 683 infrared spectrometer, and Fourier transform infrared (FTIR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in outgoing mode and the position of the band is reported in inverse frequency (cm −1 ). Mass spectra were measured using fast atom bombardment (FAB) or electrospray (ES) ionization techniques with a VG 70 FE, PE Syx API III or VG ZAB HF device. Elemental analysis was measured using a Perkin-Elmer 240C elemental analyzer. Melting points were measured on a Thomas-Hoover melting point apparatus and were not calibrated. All temperatures were reported in degrees Celsius (° C.). Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin plates were used for thin layer chromatography. Flash and attraction chromatography were performed on E. Merck Kieselgel 60 (230-400 mesh) silica gel. As shown, certain of the materials were purchased from Aldrich Chemical Co., Chemical Dynamics Corp., and Advanced Chemtech. Unless otherwise indicated, all starting materials were obtained from commercially available ones. Without further elaboration, it is believed that one of ordinary skill in the art, using the foregoing, may use the present invention to its fullest extent. These examples are intended to illustrate the invention, but not to limit the scope thereof. What is reserved to the inventor is described in the following claims. Example 1 3-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pi Preparation of Lolidine a) 3-[(tert-butoxycarbonyl) amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine To a solution of 3- (tert-butoxycarbonylamino) pyrrolidine in CH 2 Cl 2 (2.0 g, 10.74 mmol) CBZ-leucine (3.2 g, 12.88 mmol) was added. The reaction was stirred at room temperature for approximately 1 hour and sodium triacetoxyborohydride (3.4 g, 16.11 mmol) was added all at once. The reaction was stirred for a further 2 hours, diluted with ethyl acetate, washed with saturated NaHCO 3 , brine, dried (Na 2 SO 4 ), concentrated and chromatographed (5% CH 3 OH: CH 2 Cl 2 ). 4.3 g of the title compound were obtained: MS (ES +) 420 (MH +). b) 3-amino-1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine bis hydrochloride To the compound solution of Example 1 (a) in CH 3 OH (10 ml) was added 4M HCl in (4.3 g) dioxane (10 ml). The reaction was stirred at rt for 4 h and concentrated in vacuo to afford 3.97 g of the title compound: MS (ES +) 320 (MH +). c) 3-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Example 1 (b) To a solution of the compound of (2.0 g, 5.1 mmol) EDC (1.27 g, 6.37 mmol) HOBT (724 mg, 5.35 mmol) TEA (1.78 ml, 12.75 mmol) and N-BOC-leucine (1.3 g, 5.35 mmol) was added. The reaction was stirred until TLC analysis indicated the reaction was complete, diluted with ethyl acetate, washed with 5% NaHCO 3 , brine, dried (MgSO 4 ), filtered, concentrated and chromatographed (5% CH 3 OH: CH 2 Cl 2 ) to give the title compound in 2.7 g: MS (ES +) 533 (MH +). d) 3-1-leucinyl-1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine bis hydrochloride The title compound was prepared according to the method of Example 1 (b) except using the compound of Example 1 (c): MS (ES +) 433 (MH +). e) 3-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] Pyrrolidine The title compound was prepared according to the method of Example 1 (c) except for using the compound of Example 1 (d) and quinalic acid instead of N-BOC-leucine: MS (ES +) 588 (MH +). Example 2 Preparation of 1-benzyl-3-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1-benzyl-3-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 1 (c) except using 1-benzyl-3-aminopyrrolidine. MS (ES < + >) 390 (MH < + >). b) 1-benzyl-3-1-leucineyl-pyrrolidine bis hydrochloride The title compound was prepared according to the method of Example 1 (b) except using the compound of Example 2 (a): MS (ES +) 290 (MH +). c) 1-benzyl-3-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 1 (e) except using the compound of Example 2 (b): MS (ES +) 445 (MH +). Example 3 3-[[N α -4- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation The title compound was prepared according to the method of Example 1 (e) except for using 2-naphthoic acid instead of quinal acid: MS (ES +) 587 (MH < + >). Example 4 Preparation of 1-benzyl-3-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 2 (c) except for using 2-naphthoic acid instead of quinal acid: MS (ES +) 444 (MH +). Example 5 Preparation of 1-benzyl-((3S))-[[N α- (benzyloxycarbonyl) -L-leucinyl] amino] -pyrrolidine a) 1-benzyl-((3S))-(tert-butoxycarbonyl) amino-pyrrolidine ((3S))-(-)-3- (tert-butoxycarbonylamino) pyrrolidine instead of 3- (tert-butoxycarbonylamino) pyrrolidine and benzaldehyde instead of CBZ-leucine The title compound was prepared according to the method of Example 1 (a) except for: MS (ES < + >) 221.2 (M-C4H8), 277.3 (MH < + >). b) 1-benzyl-((3S))-amino-pyrrolidine bis hydrochloride To a solution of the compound of Example 5 (a) in methanol was added 1M HCl / ether. The reaction was stirred at room temperature until mass reaction indicated the reaction was complete. The reaction was concentrated in vacuo to give a white solid: MS (ES < + >) 177.0 (MH < + >). c) 1-benzyl-((3S))-[[N α- (benzyloxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 1 (c) except for using the compound of Example 5 (b) and CBZ-leucine instead of BOC-leucine: MS (ES +) 424.2 (MH +). Example 6 Preparation of 1-benzyl-((3S))-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 5 (c) except for using BOC-leucine instead of CBZ-leucine: MS (ES +) 390.5 (MH +). Example 7 ((3S))-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -Pyrrolidine Preparation a) ((3S))-[(tert-butoxycarbonyl) amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine Example 1 (a) except using ((3S))-(-)-3- (tertbutoxycarbonylamino) pyrrolidine instead of 3- (tert-butoxycarbonylamino) pyrrolidine According to the method, the title compound was prepared: MS (ES < + >) 420 (MH < + >). b) ((3S))-[(tert-butoxycarbonyl) amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 1 (b) except using the compound of Example 7 (a): MS (ES) 320 (MH +) c) (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine The title compound was prepared according to the method of Example 1 (c) except using the compound of Example 7 (b): MS (ES +) 533 (MH +). d) (3S) -1-leucineyl-1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine bis hydrochloride The title compound was prepared according to the method of Example 1 (d) except for using the compound of Example 7 (c): MS (ES +) 433 (MH +). e) (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine The title compound was prepared, except that 2-naphthoic acid was used instead of the compound of Example 7 (d) and quinal acid: MS (ES +) 587 (MH <+>). Example 8 (3R)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation a) (3R)-[(tert-butoxycarbonyl) amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine According to Example 1 (a) except that (3R)-(-)-3- (tertbutoxycarbonylamino) pyrrolidine is used instead of 3- (tert-butoxycarbonylamino) pyrrolidine The title compound was prepared: MS (ES < + >) 420 (MH < + >). b) (3R) -amino-1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine According to Example 1 (b) except for using the compound of Example 8 (a), the title compound was prepared: 320 MS (ES) (MH +) c) (3R)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine According to Example 1 (c) except for using the compound of Example 8 (b), the title compound was prepared: 533 MS (ES +) (MH +). d) (3R) -1-leucineyl-1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine bis hydrochloride According to Example 1 (d) except for using the compound of Example 8 (c), the title compound was prepared: MS (ES +) 433 (MH +). e) (3R)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine The title compound was prepared according to Example 1 (e), except that 2-naphthoic acid was used instead of the compound of Example 8 (d) and quinal acid: MS (ES +) 587 (MH +). Example 9 Preparation of 1-benzyl- (3R)-[[N α- (2-quinolinacetonoyl) -L-leucineyl] amino] -pyrrolidine a) 1-benzyl- (3R)-[(tert-butoxycarbonyl) amino] -pyrrolidine Benzaldehyde (1.3 ml, 12.88 mmol) in a solution of ((3R))-(-)-3- (tert-butoxycarbonylamino) pyrrolidine (2.0 g, 10.73 mmol) in CH 2 Cl 2 (20 ml) ). The reaction was stirred at rt for 2 h and sodium triacetoxyborohydride (5.68 g, 26.82 mmol) was added. The reaction was stirred overnight at room temperature, diluted with ethyl acetate, washed with saturated K 2 CO 3 , water, brine, dried (MgSO 4 ), filtered, concentrated and chromatographed (1: 1 hex: EtOAc) titled. Compound obtained: MS (ES < + >) 221.1 (MC 4 H 8 ), 277.2 (MH < + >) b) 1-benzyl- (3R) -amino-pyrrolidine bis hydrochloride 1N HCl / ether was added to a solution of the compound of Example 9 (a) in methanol. The suspension was stirred at room temperature until mass reaction indicated the reaction was complete. The reaction was concentrated in vacuo to afford the title compound: MS (ES < + >) 176.9 (MH < + >). c) 1-benzyl- (3R)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 1 (c) except for using N-methylmorpholine instead of the compound of Example 9 (b) and triethylamine: MS (ES +) 390.3 (MH +). d) 1-benzyl- (3R)-[(L-leucineyl) amino] -pyrrolidine bis hydrochloride HCl gas was bubbled into the compound solution of Example 9 (c) in ethyl acetate and methanol for about 2 minutes. The reaction was stirred overnight and concentrated in vacuo to afford the title compound: MS (ES +) 290.4 (MH <+>). e) 1-benzyl- (3R)-[[N α- (2-naphthylacetonoyl) -L-leucineyl] amino] -pyrrolidine To a suspension (75 mg) of the compound of Example 9 (d) was added EDC (44.3 mg), HOBT (28.4 mg) NMM (0.14 ml) and 2-naphthylacetic acid. The reaction was stirred at rt overnight, diluted with ethyl acetate, washed with saturated K 2 CO 3 , water, brine, dried (MgSO 4 ), concentrated and chromatographed to give the title compound: MS (ES +) 458.3 (MH + ). Example 10 Preparation of 1-benzyl- (3R)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 9 (e) except for replacing 2-naphthoacetic acid with 2-naphthoic acid: MS (ES < + >) 444.2 (MH < + >). Example 11 Preparation of 1-benzyl- (3R)-[[N α- (3-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 9 (e) except for using 3-quinolinecarboxylic acid instead of 2-naphthylacetic acid, the title compound was prepared: MS (ES +) 445.3 (MH <+>). Example 12 Preparation of 1-benzyl- (3R)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 9 (e) except for using quinalic acid instead of 2-naphthylacetic acid: MS (ES +) 445.2 (MH +). Example 13 Preparation of 1-benzyl- (3R)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 9 (e) except for using 3-isoquinolinecarboxylic acid instead of 2-naphthylacetic acid, the title compound was prepared: MS (ES < + >) 445.3 (MH < + >). Example 14 Preparation of 1-benzyl- (3S)-[[N α- (2-naphthylacetonoyl) -L-leucineyl] amino] -pyrrolidine a) 1-benzyl- (3S)-[(tert-butoxycarbonyl) amino] -pyrrolidine Using ((3S))-(-)-3- (tert-butoxycarbonylamino) pyrrolidine instead of (3R)-(-)-3- (tert-butoxycarbonylamino) pyrrolidine Aside from the method of Example 9 (a), the title compound was prepared: MS (ES +) 277.2 (MH < + >). b) 1-benzyl- (3S) -amino-pyrrolidine bis hydrochloride The title compound was prepared according to the method of Example 9 (b) except using the compound of Example 14 (a): MS (ES +) 177.0 (MH +). c) 1-benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 9 (c) except for using the compound of Example 14 (b): MS (ES +) 390.3 (MH +). d) 1-benzyl- (3S)-[(L-leucineyl) amino] -pyrrolidine bis hydrochloride The title compound was prepared according to the method of Example 9 (d) except using the compound of Example 14 (c): MS (ES +) 290.3 (MH +). e) 1-benzyl- (3S)-[[N α- (2-naphthylacetonoyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 9 (e) except using the compound of Example 14 (d): MS (ES +) 458.4 (MH +). Example 15 Preparation of 1-benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 14 (e) except for using 2-naphthoic acid instead of 2-naphthylacetic acid, the title compound was obtained: MS (ES +) 444.4 (MH <+>). Example 16 Preparation of 1-benzyl- (3S)-[[N α- (3-quinolinecarbonyl] -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 14 (e) except for replacing 3-quinolinecarboxylic acid instead of 2-naphthylacetic acid: MS (ES +) 445.2 (MH +). Example 17 Preparation of 1-benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 14 (e) except for using quinalic acid instead of 2-naphthylacetic acid: MS (ES +) 445.3 (MH <+>). Example 18 Preparation of 1-benzyl- (3S)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 14 (e) except for using 3-isoquinolinecarboxylic acid instead of 2-naphthylacetic acid, the title compound was prepared: MS (ES < + >) 445.3 (MH < + >). Example 19 Preparation of 1-benzyl-4-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -piperidine a) 1-benzyl-4-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -piperidine According to Example 1 (c) except for using 4-amino-1-benzylpiperidine, the title compound was prepared: MS (ES +) 404.1 (MH +). b) 1-benzyl-4-[(L-leucineyl] amino] -piperidine Compound (2.0 g) of Example 19 (a) was dissolved in 4N HCl / dioxane (100 ml). The reaction was stirred at rt for 30 min and concentrated in vacuo to yield 1.94 g of the title compound as a white solid: MS (ES +) 304.2 (MH +). c) 1-benzyl-4-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -piperidine To a solution (240 mg) of the compound of Example 19 (b) in DMF (3.0 ml) was added N-methylmorpholine (0.17 ml), HOBT (101.5 mg), 2-naphthoic acid (130.2 mg) and EDC (145.4 mg). ). The reaction was stirred overnight and poured into a rapidly stirred mixture of EtOAc, 10% Na 2 CO 3 and brine (75 ml each). This mixture was stirred for 30 minutes. The organic layer was separated and the aqueous layer was washed with ethyl acetate. The combined organic layer was washed with 10% Na 2 CO 3 , water, brine, dried (MgSO 4 ), filtered, concentrated and chromatographed to give 107 mg of the title compound (ethyl acetate): 45 (MS (ES +)) 458.5 (MH +). Example 20 Preparation of 1-benzyl-4-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -piperidine The title compound was prepared according to the method of Example 19 (c) except for replacing quinalic acid instead of 2-naphthoic acid: MS (ES +) 459.3 (MH <+>). Example 21 Preparation of 1-benzyl-4-[[N α- (benzyloxycarbonyl) -L-leucineyl] amino] -piperidine To a solution of N-benzyl-4-amino piperidine (0.50 g) in CH 2 Cl 2 (10 ml) was added CBZ-leucine (695 mg), EDC (552.5 mg) and HOBT (356.6 mg). The reaction was stirred at room temperature until TLC analysis indicated the reaction was complete. The reaction was dissolved in CHCl 3 and washed with 10% Na 2 CO 3 , brine, dried (MgSO 4 ), filtered, concentrated and chromatographed to give 0.99 g of the title compound: (3: 1 EtOAc: hexane): MS (ES < + >) 438 (MH < + >). Example 22 Preparation of 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) N-methyl-N-methoxy-3- (2-pyridyl) -phenylacetamide To a stirred solution of N-methoxy-N-methylamine hydrochloride (0.980 g, 10.0 mmol) in DMF (25 ml) N-methylmorpholine (1.21 ml, 11.0 mmol), HOBT (1.50 g, 11.1 mmol), 3- (2-pyridyl) -phenylacetic acid (2.36 g, 11.1 mmol) and EDC (2.13 g, 11.1 mmol) were added. The reaction was stirred overnight and poured into a rapidly stirred 150 ml mixture of EtOAc, 10% NaHCO 3 and brine. After stirring for 30 minutes, the layers were separated and the aqueous layer was washed with fresh EtOAc (150 ml). The combined organic layer was washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 3: 1 EtOAc: hexane) gave 2.275 g of the title compound: MS (ES +) (MH +) 257.2. b) 3- (2-pyridyl) -phenylacetaldehyde To a stirred solution of the compound of Example 22 (a) (2.2 g, 8.6 mmol) in dry THF (20 ml) at −78 ° C. was added a solution of lithium aluminum hydride in THF (22 ml, 22.0 mmol). The reaction was stirred for 2 hours, heated to 0 ° C. and stirred for 1 hour, after which 4.2 g of KHS0 4 was added in portions over 10 minutes and 100 ml of water were added in portions. The reaction mixture was filtered to remove white precipitate and the filtrate was adjusted to pH = 9 by addition of NaOH and extracted with Et 2 O (3 × 100 ml). The combined organic layers were washed with brine, then dried (Na 2 SO 4 ), filtered and concentrated to give 1.878 g of the title compound: MS (ES +) (MH +) 198.1. c) 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[N α- (tert-butoxycarbonylamino] -pyrrolidine Example 22 (b) in a stirred solution of (3S)-(-)-3- (tert-butoxycarbonylamino) pyrrolidine (672.3 mg, 3.6 mmol) in CH 2 Cl 2 (15 ml) ( 0.94 g, 4.3 mmol) was added. The reaction was stirred for 2 hours and Na (OAc) 3 BH (1.68 g, 7.9 mmol) was added. After stirring overnight, the reaction mixture was diluted with CHCl 3 (150 ml) and washed with H 2 O and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 1: 9 MeOH: EtOAc) gave 467 mg of the title compound: MS (ES +) (MH +) 368. d) 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine Example 22 (c) (440 mg, 1.2 mmol) of the compound was dissolved in 4.0N HCl in dioxane (20 ml) and stirred at room temperature for 30 minutes. The solution was concentrated to white solid and dried under high vacuum for 30 minutes. To a stirred solution of the residue in DMF (10 ml) N-methylmorpholine (400 μl, 3.6 mmol), HOBT (245.6 mg, 1.8 mmol), Boc-leucine hydrate (449.1 mg, 1.8 mmol) and EDC (352.0 mg , 1.8 mmol) was added. The reaction was stirred overnight and partitioned into 50 ml each of EtOAc, 10% Na 2 CO 3 and brine. The aqueous layer was washed with fresh EtOAc (50 ml) and the combined organic layers were washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 5:95 MeOH: EtOAc) gave 204 mg of the title compound: MS (ES +) (MH +) 481.4. e) 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α -L-leucineyl] amino] -pyrrolidine dihydrochloride Example 22 (d) (200 mg, 0.42 mmol) of the compound was dissolved in 4.0N HCl in dioxane (25 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum for 3 hours to give the title compound: MS (ES +) (MH +) 381.4. f) 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 22 (c) (440 mg, 1.2 mmol) in DMF (2 ml) N-methylmorpholine (62 μl, 0.56 mmol), HOBT (31.8 mg, 0.24 mmol), 2- Naphthoic acid (37.6 mg, 0.22 mmol) and EDC (41.2 mg, 0.22 mmol) were added. The reaction was stirred overnight and partitioned into 50 ml each of EtOAc, 10% Na 2 CO 3 and brine. The aqueous layer was washed with fresh EtOAc (50 ml) and the combined organic layers were washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 5:95 MeOH: EtOAc) gave 40.1 mg of the title compound: MS (ES +) (MH +) 535.4. Example 23 Preparation of 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 22 (f) except using 2-quinolinecarboxylic acid: MS (ES +) (MH +) 536.4. Example 24 Preparation of 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 22 (f) except using 3-isoquinolinecarboxylic acid: MS (ES +) (MH +) 536.4. Example 25 Preparation of 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[N α- (tert-butoxycarbonylamino] -pyrrolidine The title compound was prepared according to the method of Example 22 (c) except using (3R)-(+)-3- (tertbutoxycarbonylamino) pyrrolidine: MS (ES +) (MH + ) 368.4. b) 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine Example 25 The title compound was prepared according to the method of Example 22 (d) except for using the compound of (a): MS (ES +) (MH +) 481.4. c) 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α -L-leucineyl] amino] -pyrrolidine dihydrochloride The title compound was prepared according to the method of Example 22 (e), except using the compound of Example 25 (b): MS (ES +) (MH +) 381.4. d) 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine Example 25 The title compound was prepared according to the method of Example 22 (f) except using the compound of (c): MS (ES +) (MH +) 535.3. Example 26 Preparation of 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 25 (d) except for using 3-isoquinolinecarboxylic acid, the title compound was prepared: MS (ES +) (MH +) 536.3. Example 27 Preparation of 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 25 (d) except for using 2-quinolinecarboxylic acid, the title compound was prepared: MS (ES +) (MH +) 536.3. Example 28 Preparation of 1- (1-adamantanecarbonyl)-(3R)-[[N α- (4-pyridylmethoxycarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (1-adamantanecarbonyl)-(3R)-[[N α- (tert-butyloxycarbonyl) -L-leucineyl] amino] -pyrrolidine N-methylmor in a stirred aqueous solution of (3R)-(+)-3- (tert-butoxycarbonylamino) pyrrolidine (1.87 g, 10.0 mmol) in CH 2 Cl 2 (30 ml) at 0 ° C. Pauline (1.65 ml, 15.0 mmol) and 1-adamantylcarbonyl chloride (2.99 g, 15.0 mmol) were added. The reaction was stirred overnight and slowly heated to room temperature and diluted with 200 ml of CHCl 3 , washed with 5% NaHCO 3 , H 2 0, 1N HCl, H 2 0, and brine, then dried (MgSO 4 ), Filtration and concentration gave 4.66 g of the title compound: MS (ES +) (MH +) 349.4. b) 1- (1-adamantanecarbonyl)-(3R) -aminopyrrolidine hydrochloride Compound (4.6 g) of Example 28 (a) was dissolved in 4.0N HCl in dioxane (100 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum for 2 hours to give the title compound: MS (ES +) (MH +) 249.1. c) 1- (1-adamantanecarbonyl)-(3R)-[[N α- (4-pyridylmethoxycarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 28 (b) (143.2 mg, 0.50 mmol) in DMF (2 ml) N-methylmorpholine (83 μl, 0.75 mmol), HOBT (101.5 mg, 0.75 mmol), 4- Inoc-leucine (201.5 mg, 0.76 mmol) and EDC (146.0 mg, 0.76 mmol) were added. The reaction was stirred overnight and partitioned between 50 ml of EtOAc, 10% Na 2 CO 3 and brine. The aqueous layer was washed with fresh EtOAc (50 ml) and the combined organic layers were washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 2:98 MeOH: EtOAc) gave 109.0 mg of the title compound: MS (ES +) (MH +) 497.5. Example 29 Preparation of 1- (1-adamantanecarbonyl)-(3S)-[[N α- (4-pyridylmethoxycarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (1-adamantanecarbonyl)-(3S)-[[N α- (tert-butyloxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 28 (a), except using (3S)-(-)-3- (tertbutoxycarbonylamino) pyrrolidine: MS (ES +) (MH + ) 349.5. b) 1- (1-adamantanecarbonyl)-(3S) -aminopyrrolidine hydrochloride Example 29 The title compound was prepared according to the method of Example 28 (b) except using the compound of (a): MS (ES +) (MH +) 249.1. c) 1- (1-adamantanecarbonyl)-(3S)-[[N α- (4-pyridylmethoxycarbonyl) -L-leucineyl] amino] -pyrrolidine According to Example 28 (c) except for using the compound of Example 29 (b), the title compound was prepared: MS (ES +) (MH +) 407.4. Example 30 (3R)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Preparation of Bonyl) amino] pentyl] -pyrrolidine a) (3R)-[N α- (tert-butoxycarbonyl) amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine N-CBZ-leucine in a stirred solution of (3R)-(+)-3- (tert-butoxycarbonylamino) pyrrolidine (2 g, 10.7 mmol) in CH 2 Cl 2 (200 ml) ( 3.2 g, 12.9 mmol) was added. The reaction was stirred for 2 hours and Na (OAc) 3 BH (3.4 g, 16.1 mmol) was added. After stirring overnight, the reaction mixture was diluted with CHCl 3 (150 ml) and washed with 5% NaHCO 3 and brine, then dried (MgSO 4), filtered and concentrated. Column chromatography (silica gel, 3:97 MeOH: CH 2 Cl 2 ) gave 3.4 g of the title compound: MS (ES +) (MH +) 420. b) (3R) -amino-1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine dihydrochloride Example 30 (a) (3.4 g) of the compound was dissolved in 4.0N HCl in dioxane (50 ml) and stirred at room temperature for 1 hour. The solution was concentrated in vacuo and dried under high vacuum to afford 3.37 g of the title compound: MS (ES +) (MH +) 320. c) (3R)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine To a stirred solution of the compound of Example 30 (b) (2.36 g, 6.0 mmol) in DMF (25 ml) N-methylmorpholine (2.0 ml, 18.2 mmol), HOBT (1.22 g, 9.0 mmol), Boc- Leucine hydrate (2.25 g, 9.0 mmol) and EDC (1.73 g, 9.0 mmol) were added. The reaction was stirred for 3 hours and partitioned between 150 ml of EtOAc, 10% Na 2 CO 3 and brine. The aqueous layer was washed with fresh EtOAc (150 ml) and the combined organic layers were washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 2: 1 EtOAc: hexanes) gave 2.78 g of the title compound: MS (ES +) (MH +) 533.6. d) (3R)-[[N α -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine dihydrochloride Example 30 (c) (2.7 g) of the compound was dissolved in 4.0N HCl in dioxane (100 ml) and stirred at room temperature for 1 hour. The solution was concentrated in vacuo and azeotropically dried with toluene to give a tan solid which was stored under high vacuum overnight to give 2.45 g of the title compound: MS (ES +) (MH +) 433.3. e) (3R)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyl Oxycarbonyl) amino] pentyl] -pyrrolidine To a stirred solution of the compound of Example 30 (d) (101.4 mg, 0.2 mmol) in DMF (1 ml) was added N-methylmorpholine (66 μl, 0.6 mmol), HOBT (42.2 mg, 0.3 mmol), benzo [ b] thiophene-2-carboxylic acid (53.3 mg, 0.3 mmol) and EDC (57.8 mg, 0.3 mmol) were added. The reaction was stirred overnight and partitioned between 50 ml of EtOAc, 10% Na 2 CO 3 and brine. The aqueous layer was washed with fresh EtOAc (50 ml) and the combined organic layers were washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 3: 1 EtOAc: hexanes) gave 80.4 mg of the title compound: MS (ES +) (MH +) 593.4. Example 31 (3R)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Preparation of Pentyl] -Pyrrolidine The title compound was prepared according to the method of Example 30 (e), except using 3,4-dimethoxybenzoic acid: MS (ES +) (MH +) 597.4. Example 32 (3R)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Preparation of Pentyl] -Pyrrolidine The title compound was prepared according to the method of Example 30 (e), except using benzofuran-2-carboxylic acid: MS (ES +) (MH +) 577.2. Example 33 (3R)-[[N α- (benzothiazole-6-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -Pyrrolidine Preparation The title compound was prepared according to the method of example 30 (e) except using benzothiazole-6-carboxylic acid: MS (ES +) (MH +) 594.4. Example 34 (3R)-[[N α- (indol-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation The title compound was prepared according to the method of Example 30 (e) except using indole-2-carboxylic acid: MS (ES +) (MH +) 576.3. Example 35 (3R)-[[N α- (4-fluorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] Preparation of Pyrrolidine The title compound was prepared according to the method of Example 30 (e) except using 4-fluorobenzoic acid: MS (ES +) (MH +) 555.3. Example 36 (3R)-[[N α- (4-methoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] Preparation of Pyrrolidine The title compound was prepared according to the method of Example 30 (e) except using p-4-methoxybenzoic acid: MS (ES +) (MH +) 567.4. Example 37 (3R)-[[N α- (3,4-dichlorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation The title compound was prepared according to the method of example 1 (e) except using 3,4-dichlorobenzoic acid: MS (ES +) (MH +) 605.2. Example 38 (3R)-[[N α- (thiophene-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Preparation of Pentyl] -Pyrrolidine The title compound was prepared according to the method of Example 30 (e) except using thiophene-3-carboxylic acid: MS (ES +) (MH +) 543.4. Example 39 (3R)-[[N α- (4-biphenylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation To a stirred solution of the compound of Example 30 (d) (102.3 mg, 0.2 mmol) in CH 2 Cl 2 (1 ml) at 0 ° C. N-methylmorpholine (66 μl, 0.6 mmol) and 4-biphenylcarb Bonyl chloride (65.2 mg, 0.3 mmol) was added. The reaction was stirred overnight, diluted with CHCl 3 , washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 3: 1 EtOAc: hexanes) gave 55.1 mg of the title compound: MS (ES +) (MH +) 613.5. Example 40 (3R)-[[N α- (5-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbine Preparation of Bonyl) amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 30 (e), except using 5-methoxybenzofuran-2-carboxylic acid: MS (ES +) (MH +) 607.4. Example 41 (3R)-[[N α- (5-chlorobenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl ) Amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 30 (e), except using 5-chlorobenzofuran-2-carboxylic acid: MS (ES +) (MH +) 611.4. Example 42 (3R)-[[N α- (7-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Preparation of Bonyl) amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 30 (e), except using 7-methoxybenzofuran-2-carboxylic acid: MS (ES +) (MH +) 607.4. Example 43 (3R)-[[N α- (3-chlorobenzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[( Preparation of benzyloxycarbonyl) amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 30 (e), except using 3-chlorobenzo [b] thiophene-2-carboxylic acid: MS (ES +) (MH +) 627.3. Example 44 (3R)-[[N α- (3- (2-pyridyl) benzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) Preparation of Amino] pentyl] -pyrimidine According to the method of Example 30 (e) except for using 3- (2-pyridyl) benzoic acid, the title compound was prepared: MS (ES +) (MH +) 614.4. Example 45 (3S)-[[N α- (benzo [b] thiophene-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbine Preparation of Bonyl) amino] pentyl] -pyrrolidine a) (3S)-[N α- (tert-butoxycarbonyl) amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine According to the method of Example 30 (e) except for using (3S)-(-)-3- (tert-butoxycarbonylamino) pyrrolidine, the title compound was prepared: MS (ES +) ( MH +) 420. b) (3S) -amino-1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine dihydrochloride The title compound was prepared according to the method of Example 30 (b) except using the compound of Example 45 (a): MS (ES +) (MH +) 320. c) (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine The title compound was prepared according to the method of Example 30 (c) except using Example 45 (b): MS (ES +) (MH +) 533.5. d) (3S)-[[N α -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pyrrolidine dihydrochloride The title compound was prepared, following the method of Example 30 (d), except using the compound of Example 45 (c): MS (ES +) (MH +) 433.3. e) (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyl Oxycarbonyl) amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 30 (e), except using the compound of Example 45 (d): MS (ES +) (MH +) 593.4. Example 46 3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation The title compound was prepared according to the method of Example 45 (e) except using 3,4-dimethoxybenzoic acid: MS (ES +) (MH +) 597.5. Example 47 (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Preparation of Pentyl] -Pyrrolidine The title compound was prepared according to the method of Example 45 (e) except using benzofuran-2-carboxylic acid: MS (ES +) (MH +) 577.4. Example 48 (3S)-[[N α -4- (benzothiazole-6-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl ) Amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 45 (e) except using the benzothiazole-6-carboxylic acid: MS (ES +) (MH +) 594.4. Example 49 (3S)-[[N α- (indol-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation The title compound was prepared according to the method of Example 45 (e) except using indole-2-carboxylic acid: MS (ES +) (MH +) 576.4. Example 50 (3S)-[[N α- (4-fluorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] Preparation of Pyrrolidine According to the method of Example 45 (e) except using 4-fluorobenzoic acid, the title compound was prepared: MS (ES +) (MH +) 555.3. Example 51 (3S)-[[N α- (4-methoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2 [[(benzyloxycarbonyl) amino] pentyl]- Preparation of Pyrrolidine The title compound was prepared according to the method of Example 45 (e) except using p-4-methoxybenzoic acid: MS (ES +) (MH +) 567.3. Example 52 (3S)-[[N α- (3,4-dichlorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation The title compound was prepared according to the method of Example 45 (e), except using 3,4-dichlorobenzoic acid: MS (ES +) (MH +) 605.2. Example 53 (3S)-[[N α- (thiophene-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Preparation of Pentyl] -Pyrrolidine The title compound was prepared according to the method of Example 45 (e) except using thiophene-3-carboxylic acid: MS (ES +) (MH +) 543.2. Example 54 (3S)-[[N α- (4-biphenylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine Preparation Example 45 The title compound was prepared according to the method of Example 39 except for using the compound of (e): MS (ES +) (MH +) 613.4. Example 55 (3S)-[[N α- (5-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4methyl-2-[[(benzyloxycarbonyl ) Amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 45 (e) except using 5-methoxybenzofuran-2-carboxylic acid: MS (ES +) (MH +) 607.4. Example 56 (3S)-[[N α- (5-chlorobenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl ) Amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 45 (e), except using 5-chlorobenzofuran-2-carboxylic acid: MS (ES +) (MH +) 611.4. Example 57 (3S)-[[N α- (7-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Preparation of Bonyl) amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 45 (e), except using 7-methoxybenzofuran-2-carboxylic acid: MS (ES +) (MH +) 607.4. Example 58 (3S)-[[N α- (3-chlorobenzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[( Preparation of benzyloxycarbonyl) amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 45 (e) except using 3-chlorobenzo [b] thiophene-2-carboxylic acid: MS (ES +) (MH +) 627.2. Example 59 (3S)-[[N α- (3- (2-pyridyl) benzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) Preparation of Amino] pentyl] -pyrrolidine The title compound was prepared according to the method of Example 45 (e), except using 3- (2-pyridyl) benzoic acid: MS (ES +) (MH +) 614.4. Example 60 Preparation of 1- (4-phenyl) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (2,2,2-trichloroethylcarbonyl)-(3S)-[[N α- (tert-butoxycarbonyl) amino] -pyrrolidine N-Methylmor in a stirred solution of (3S)-(-)-3- (tert-butoxycarbonylamino) pyrrolidine (10 G, 53.7 mmol) in CH 2 Cl 2 (150 ml) at 0 ° C. Pauline (6.50 ml, 59.1 mmol) and 2,2,2-trichloroethyl chloropromate (8.20 ml, 59.6 mmol) were added. After stirring overnight, the mixture was slowly heated to room temperature, the reaction mixture was concentrated to 1/2 of the original volume, diluted with CHCl 3 (250 ml), 5% NaHCO 3 , H 2 O, 1N HCl, H 2 O and Brine, then dried (MgSO 4 ), filtered and concentrated to give 23.98 g of the title compound: 1 H-NMR (400 MHz, CDCl 3 ): d (ppm) 4.74 (s, 2H); 4.66 (br m, 1 H); 4.25 (br m, 1 H); 3.72 (m, 1 H); 3.56 (m, 2 H); 3.33 (m, 1 H); 2.19 (m, 1 H); 1.87 (m, 1 H); 1.45 (s, 9 H). b) 1- (2,2,2-trichloroethylcarbonyl)-(3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine Example 60 (a) (23.9 g) of the compound was dissolved in 4.0N HCl in dioxane (200 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and stored under high vacuum for 30 minutes. To a stirred solution of the residue in DMF (200 ml) N-methylmorpholine (8.90 ml, 80.9 mmol), HOBT (10.88 g, 80.5 mmol), Boc-leucine hydrate (20.09 g, 80.6 mmol) and EDC (15.44 g , 80.6 mmol) was added. The reaction was stirred overnight and partitioned between EtOAc (300 ml), 10% Na 2 CO 3 (150 ml) and brine (150 ml). The aqueous layer was washed with fresh EtOAc (100 ml) and the combined organic layers were washed with 1N HCl, H 2 0, 10% Na 2 CO 3 , H 2 O and brine, then dried (MgSO 4 ), filtered and concentrated. 27.88 g of the title compound were obtained: MS (ES +) (MH +) 474.1. c) (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 60 (b) (27.7 g) in THF (200 ml) was added a solution of 1N NH 4 OAc (pH 7-7.5, 40 ml) followed by zinc powder (25.06 g). . The reaction was stirred at room temperature for 3 hours and the slurry was filtered through a pad of celite and then washed several times with CHCl 3 . The combined filtrates were concentrated to remove THF, diluted with additional CHCl 3 (300 ml) and washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated to 16.34 g of title. Compound obtained: MS (ES +) (MH < + >) 300.2. d) 1- (4-phenyl) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 60 (c) (1.51 g, 5.0 mmol) in CH 2 Cl 2 (10 ml) was added 4,4-4-biphenylcarboxaldehyde (1.09 g, 6.0 mmol). The reaction was stirred for 2 hours and Na (OAc) 3 (2.34 g, 11.0 mmol) was added. After stirring overnight, the reaction mixture was diluted with CHCl 3 (100 ml) and washed with 5% NaHCO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 2: 1 EtOAc: hexanes to 3: 1 EtOAc: hexanes) gave 1.68 g of the title compound: MS (ES +) (MH +) 466.4. Example 61 Preparation of 1- (4-phenyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (4-phenyl) benzyl- (3S)-[[N α -L-leucineyl] amino] -pyrrolidine dihydrochloride Example 60 (d) (1.57 g, 3.4 mmol) of the compound was dissolved in 4.0N HCl in dioxane (25 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum for 30 minutes to give the title compound: MS (ES +) (MH +) 366.4. b) 1- (4-phenyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 61 (a) (132.9 mg, 0.30 mmol) in DMF (1 ml) N-methylmorpholine (100 μl, 0.91 mmol), HOBT (62.0 mg, 0.46 mmol), 2- Naphthoic acid (78.4 mg, 0.46 mmol) and EDC (87.3 mg, 0.46 mmol) were added. The reaction was stirred overnight and partitioned between 50 ml of EtOAc, 10% Na 2 CO 3 and brine. The aqueous layer was washed with fresh EtOAc (50 ml) and the combined organic layers were washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 2: 1 EtOAc: hexanes) gave 102.8 mg of the title compound: MS (ES +) (MH +) 520.3. Example 62 Preparation of 1- (4-phenyl) benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 61 (b) except using 2-quinolinecarboxylic acid: MS (ES +) (MH +) 521.3. Example 63 Preparation of 1- (4-phenyl) benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 61 (b) except using 3,4-dimethoxybenzoic acid: MS (ES +) (MH +) 530.3. Example 64 Preparation of 1- (4-phenyl) benzyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 61 (b) except using benzofuran-2-carboxylic acid, the title compound was prepared: MS (ES +) (MH +) 510.3. Example 65 Preparation of 1- (4-phenyl) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 61 (b) except using benzo [b] thiophene-2-carboxylic acid: MS (ES +) (MH +) 526.4. Example 66 Preparation of 1- (4-phenyl) benzyl- (3S)-[[N α- (benzyloxycarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred suspension of the compound of Example 61 (a) (132.9 mg, 0.30 mmol) in CH 2 Cl 2 (2 ml) at 0 ° C. was added N-methylmorpholine (132 μl, 1.20 mmol) and benzyl chloroformate ( 53 μl, 0.36 mmol) was added. The reaction was stirred overnight, slowly heated to room temperature, diluted with CHCl 3 (100 ml) and washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, EtOAc) gave 94.0 mg of the title compound: MS (ES +) (MH +) 500.3. Example 67 Preparation of 1- (2-phenyl) ethyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 60 (d), except using phenylacetaldehyde: MS (ES +) (MH +) 404.4. Example 68 Preparation of 1- (2-phenyl) ethyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (2-phenyl) ethyl- (3S)-[[N α -L-leucineyl] amino] -pyrrolidine Example 67 (1.13 g, 2.8 mmol) of the compound was dissolved in 4.0N HCl in dioxane (25 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum for 30 minutes to give the title compound: MS (ES +) (MH +) 304.3. b) 1- (2-phenyl) ethyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 61 (b) except using the compound of Example 68 (a): MS (ES +) (MH +) 458.3. Example 69 Preparation of 1- (2-phenyl) ethyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 68 (b) except using 2-quinolinecarboxylic acid: MS (ES +) (MH +) 459.5. Example 70 Preparation of 1- (2-phenyl) ethyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 68 (b) except using benzo [b] thiophene-2-carboxylic acid: MS (ES +) (MH +) 464.3. Example 71 Preparation of 1- (2-phenyl) ethyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 68 (b) except using benzofuran-2-carboxylic acid: MS (ES +) (MH +) 448.3. Example 72 Preparation of 1- (2-phenyl) ethyl- (3S)-[[N α- (3-chlorobenzo [b] thiophene-2-carbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of example 68 (b) except using 3-chlorobenzo [b] thiophene-2-carboxylic acid: MS (ES +) (MH +) 498.1. Example 73 Preparation of 1- (4-phenoxy) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 60 (d) except using 4-phenoxybenzaldehyde: MS (ES +) (MH <+>) 482.4. Example 74 Preparation of 1- (4-phenoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (4-phenoxy) benzyl- (3S)-[[N α -L-leucineyl] amino] -pyrrolidine dihydrochloride Example 73 (1.52 g, 3.2 mmol) of the compound was dissolved in 4.0N HCl in dioxane (25 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum for 30 minutes to give the title compound: MS (ES +) (MH +) 382.4. b) 1- (4-phenoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 61 (b) except using the compound of Example 74 (a): MS (ES +) (MH +) 536.3. Example 75 Preparation of 1- (4-phenoxy) benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 74 (b) except using 2-quinolinecarboxylic acid: MS (ES +) (MH +) 537.3. Example 76 Preparation of 1- (4-phenoxy) benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucinyl] amino] -4-pyrrolidine The title compound was prepared according to the method of Example 74 (b) except using 3,4-dimethoxybenzoic acid: MS (ES +) (MH +) 546.3. Example 77 Preparation of 1- (4-phenoxy) benzyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 74 (b) except using benzofuran-2-carboxylic acid: MS (ES +) (MH +) 526.4. Example 78 Preparation of 1- (4-phenoxy) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 74 (b) except using benzo [b] thiophene-2-carboxylic acid: MS (ES +) (MH +) 542.3. Example 79 Preparation of 1- (4-fluoro) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 60 (d) except using 4-fluorobenzaldehyde: MS (ES +) (MH +) 408.3. Example 80 Preparation of 1- (4-fluoro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (4-fluoro) benzyl- (3S)-[[N α -L-leucineyl] amino] -pyrrolidine dihydrochloride Example 79 (508 mg, 1.25 mmol) of the compound was dissolved in 4.0N HCl in dioxane (25 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum for 30 minutes to give the title compound: MS (ES +) (MH +) 308.3. b) 1- (4-fluoro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 61 (b) except using the compound of Example 80 (a): MS (ES +) (MH +) 462.3. Example 81 Preparation of 1- (4-fluoro) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 80 (b) except using benzo [b] thiophene-2-carboxylic acid: MS (ES +) (MH +) 468.3. Example 82 Preparation of 1- (4-cyano) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 60 (d) except using 4-cyanobenzaldehyde, the title compound was prepared: MS (ES +) (MH +) 415.4. Example 83 Preparation of 1- (4-cyano) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (4-cyano) benzyl- (3S)-[[N α -L-leucineyl] amino] -pyrrolidine dihydrochloride Example 82 (512 mg, 1.23 mmol) of the compound was dissolved in 4.0N HCl in dioxane (25 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum for 30 minutes to give the title compound: MS (ES +) (MH +) 315.4. b) 1- (4-cyano) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 61 (b) except using the compound of Example 83 (a): MS (ES +) (MH +) 469.5. Example 84 Preparation of 1-benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine a) 1-benzyl- (3S)-[N α- (tert-butoxycarbonyl) amino] -pyrrolidine Benzaldehyde (6.6 ml, 64.9 mmol) in a stirred solution of (3S)-(-)-3- (tert-butoxycarbonylamino) pyrrolidine (10 g, 53.7 mmol) in CH 2 Cl 2 (125 ml) ). The reaction was stirred for 2 hours and Na (OAc) 3 (25.05 g, 118.2 mmol) was added. After stirring overnight, a small amount of 5% NaHCO 3 was added until the bubbles disappeared. The reaction mixture was diluted with CHCl 3 (150 ml) and washed with 5% NaHCO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 1: 1 EtOAc: hexane) gave 11.5 g of the title compound: MS (ES +) (MH +) 277.2. b) 1-benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine Example 84 (a) (11.0 g, 39.8 mmol) was dissolved in 4.0N HCl in dioxane (300 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum. To a stirred solution of the residue in DMF (100 ml) N-methylmorpholine (13.1 ml, 119.1 mmol), HOBT (8.07 g, 59.7 mmol), Boc-leucine hydrate (14.89 g, 59.7 mmol) and EDC (11.44 g) , 59.7 mmol) was added. The reaction was stirred overnight, washed with EtOAc (500 ml) and washed with 1: 1 10% Na 2 CO 3 : brine (300 ml). The aqueous layer was washed with fresh EtOAc (150 ml) and the combined organic layers were washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 1: 2 EtOAc: hexanes to 1: 1 EtOAc: hexanes) gave 13.5 g of the title compound: MS (ES +) (MH +) 390.4. c) 1-benzyl- (3S)-[[N α -L-leucineyl] amino] -pyrrolidine dihydrochloride Example 84 (b) (11.6 g, 29.8 mmol) of the compound was dissolved in 4.0N HCl in dioxane (300 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum to afford the title compound: MS (ES +) (MH +) 290.4. d) 1-benzyl- (3S)-[[N α- (benzo [b] thiophene-2-carbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 84 (c) (109.2 mg, 0.30 mmol) in DMF (1 ml) was added N-methylmorpholine (100 μl, 0.91 mmol), HOBT (61.6 mg, 0.46 mmol), benzo [ b] thiophene-2-carboxylic acid (80.8 mg, 0.45 mmol) and EDC (86.6 mg, 0.45 mmol) were added. The reaction was stirred overnight and partitioned between 50 ml of EtOAc, 10% Na 2 CO 3 and brine. The aqueous layer was washed with fresh EtOAc (50 ml) and the combined organic layers were washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 4: 1 EtOAc: hexane) gave 85.0 mg of the title compound: MS (ES +) (MH +) 450.0. Example 85 Preparation of 1-benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 84 (d) except using 3,4-dimethoxybenzoic acid: MS (ES +) (MH +) 454.4. Example 86 Preparation of 1-benzyl- (3S)-[[N α- (3- (2-dimethylaminoethoxy) -4-methoxybenzoyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 84 (d) except for using 3- (2-dimethylaminoethoxy) -4-methoxybenzoic acid: MS (ES +) (MH +) 511.2. Example 87 Preparation of 1- (4-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1-benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 84 (c) (7.25 g, 20.0 mmol) in DMF (50 ml) N-methylmorpholine (6.60 ml, 60.0 mmol), HOBT (4.05 g, 30.0 mmol), 2- Naphthoic acid (5.17 g, 30.0 mmol) and EDC (5.76 g, 30.1 mmol) were added. The reaction was stirred overnight and partitioned between EtOAc (300 ml), 10% Na 2 CO 3 (150 ml) and brine (150 ml). The aqueous layer was washed with fresh EtOAc (150 ml) and the combined organic layers were washed with 10% Na 2 CO 3 , brine and then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 3: 1 EtOAc: hexanes to EtOAc) gave 5.7 g of title compound: MS (ES +) (MH < + >) 444.0. b) (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine 1-chloroethyl chloroformate in dichloroethane in a stirred suspension of the compound of Example 87 (a) (2.22 g, 5.00 mmol) in anhydrous dichloroethane (10 ml) at 0 ° C. in an oven-dried flask at 0 ° C. under nitrogen atmosphere. (600 μl, 5.56 mmol) was added dropwise over 10 minutes. After stirring for 15 min at 0 ° C., the reaction was refluxed for 1.5 h, cooled to rt and concentrated. The residue was dissolved in anhydrous MeOH (10 ml) and refluxed overnight. The reaction was cooled to room temperature, concentrated, dissolved in H 2 0 and basified to pH 9-9.5 by addition of solid Na 2 CO 3 . The aqueous solution was extracted with CHCl 3 (2 × 100 ml) and the combined organic layers were washed with brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 10:90 MeOH: CHCl 3 to 10: 90: 0.1 MeOH: CHCl 3 : NH 4 0H) gave 0.82 g of the title compound: MS (ES +) (MH +) 354.3. c) 1- (4-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine CH 2 Cl 2 (1 ml) To a stirred solution of the compound of Example 87 (b) (106.5 mg, 0.30 mmol) was added 4-nitrobenzaldehyde (55.5 mg, 0.37 mmol). The reaction was stirred for 1.5 h and Na (OAc) 3 (141.3 mg, 0.67 mmol) was added. After stirring overnight, the reaction mixture was diluted with CHCl 3 (100 ml) and washed with 5% NaHCO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, EtOAc) gave 88.0 mg of the title compound: MS (ES +) (MH +) 489.3. Example 88 Preparation of 1- (4- (N, N-dimethylamino) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) except using 4- (N, N-dimethylamino) benzaldehyde: MS (ES +) (MH +) 487.1. Example 89 Preparation of 1- (4-methoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine Using the replacement of p-anisaldehyde and following the method of Example 87 (c), the title compound was prepared: MS (ES +) (MH +) 474.4. Example 90 Preparation of 1- (4-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 87 (c) except for using 4-pyridinecarboxaldehyde, the title compound was prepared: MS (ES +) (MH +) 445.4. Example 91 Preparation of 1- (4-carboxymethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) except using methyl-4-formylbenzoate: MS (ES +) (MH +) 502.3. Example 92 Preparation of 1- (3,4-methylenedioxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine Using the substitution of the piperonal and following the method of Example 87 (c) the title compound was prepared: MS (ES +) (MH +) 488.2. Example 93 Preparation of 1- (2-naphthyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) except using 2-naphthaldehyde: MS (ES +) (MH +) 494.2. Example 94 Preparation of 1- (3-Indolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) except for using indole-3-carboxaldehyde: MS (ES +) (MH +) 483.4. Example 95 Preparation of 1- (2-quinolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) except for using quinoline-2-carboxaldehyde: MS (ES +) (MH +) 495.4. Example 96 Preparation of 1- (3-quinolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) except for using quinoline-3-carboxaldehyde: MS (ES +) (MH +) 495.3. Example 97 Preparation of 1- (1-naphthyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) but using 1-naphthaldehyde: MS (ES +) (MH +) 494.3. Example 98 Preparation of 1- (4-quinolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) except for using quinoline-4-carboxaldehyde: MS (ES +) (MH +) 495.3. Example 99 Preparation of 1- (3-pyrrolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) but using pyrrole-2-carboxaldehyde: MS (ES +) (MH +) 433.3. Example 100 Preparation of 1- (3-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 87 (c) except for using pyridine-3-carboxaldehyde, the title compound was prepared: MS (ES +) (MH +) 445.2. Example 101 Preparation of 1- (2-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 87 (c) except for using pyridine-2-carboxaldehyde: MS (ES +) (MH +) 445.1. Example 102 Preparation of 1- (3-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared following the method of Example 87 (c) except using 3-nitrobenzaldehyde: MS (ES +) (MH +) 489.3. Example 103 Preparation of 1- (4-acetamido) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine a) 1- (2,2,2-trichloroethyl) carbonyl- (3S)-[[N α- (tert-butoxycarbonyl) amino] -pyrrolidine N-methylmor in a stirred solution of (3S)-(-)-3- (tert-butoxycarbonylamino) pyrrolidine (10 g, 53.7 mmol) in CH 2 Cl 2 (150 ml) at 0 ° C. Pauline (6.50 ml, 59.1 mmol) and 2,2,2-trichloroethyl chloroformate (8.20 ml, 59.6 mmol) were added. After stirring overnight, the mixture was slowly heated to room temperature and the reaction mixture was diluted with CHCl 3 (250 ml) and washed with 5% NaHCO 3 , H 2 0, 1N HCl, H 2 0 and brine, then dried (MgSO 4 ). , Filtered and concentrated to give 19.96 g of the title compound: 1 H-NMR (400 MHz, CDCl 3 ): d (ppm) 4.74 (s, 2H); 4.66 (br m, 1 H); 4.25 (br m, 1 H); 3.72 (m, 1 H); 3.56 (m, 2 H); 3.33 (m, 1 H); 2.19 (m, 1 H); 1.87 (m, 1 H); 1.45 (s, 9 H). b) 1- (2,2,2-trichloroethyl) carbonyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine Example 103 (a) (19.9 g) of the compound was dissolved in 4.0N HCl in dioxane (400 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and stored under high vacuum. To a stirred solution of the residue in DMF (200 ml) N-methylmorpholine (8.90 ml, 80.9 mmol), HOBT (10.88 g, 80.5 mmol), Boc-leucine hydrate (20.10 g, 80.6 mmol) and EDC (15.45 g) , 80.7 mmol) was added. The reaction was stirred overnight and concentrated to remove most of the DMF, diluted with EtOAc (300 ml) and washed with brine (150 ml). The aqueous layer was washed with fresh EtOAc (100 ml) and the combined organic layers were washed with 1N HCl, H 2 0, 10% Na 2 CO 3 , H 2 O and brine, then dried (MgSO 4 ), filtered and concentrated. 24.64 g of the title compound were obtained: 1 H-NMR (400 MHz, CDCl 3 ): d (ppm) 6.55 (br m, 1H); 4.88 (m, 1 H); 4.76 (s, 2 H); 4.48 (m, 1 H); 4.03 (m, 1 H); 3.75 (m, 1 H); 3.58 (m, 2 H); 3.33 (m, 1 H); 2.19 (m, 1 H); 1.88 (m, 1 H); 1.64 (m, 2 H); 1.49 (m, 1 H); 1.44 (s, 9 H); 0.93 (m, 6 H). c) 1- (2,2,2-trichloroethyl) carbonyl- (3S)-[[N α -L-leucineyl] amino] -pyrrolidine hydrochloride Example 103 (b) (24.5 g) was dissolved in 4.0N HCl in dioxane (500 ml) and stirred at room temperature for 1 hour. The solution was concentrated to white solid and dried under high vacuum to afford the title compound: MS (ES +) (MH +) 375. d) 1- (2,2,2-trichloroethyl) carbonyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 103 (c) (10-28 g, 25.0 mmol) in DMF (75 ml) N-methylmorpholine (4.2 ml, 38.2 mmol), HOBT (5.07 g, 37.5 mmol), 2-naphthoic acid (6.46 g, 37.5 mmol) and EDC (7.18 g, 37.5 mmol) were added. The reaction was stirred overnight and concentrated to remove most of the DMF and partitioned between EtOAc (300 ml), 1N HCl (150 ml) and brine (150 ml). The aqueous layer was washed with fresh EtOAc (150 ml) and the combined organic layers were washed with 1N HCl, H 2 0, 10% Na 2 CO 3 , H 2 0 and brine, then dried (MgSO 4 ), filtered and concentrated. It was. Column chromatography (silica gel, 1: 2 EtOAc: hexanes to 1: 1 EtOAc: hexanes) gave 9.74 g of the title compound: MS (ES +) (MH +) 528.1. e) (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 103 (d) (9.65 g) in THF (75 ml) was added a solution of 1N NH 4 OAc (pH 7-7.5, 15 ml) followed by zinc powder (9.53 g). . The reaction was stirred at rt for 5 h, fresh zinc (4 g) was added and the reaction stirred overnight. The slurry was filtered through a pad of celite and washed several times with THF. The combined filtrates were concentrated to remove THF, diluted with CHCl 3 (300 ml), washed with 10% Na 2 CO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 10:90 MeOH: CHCl 3 to 10: 90: 0.25 MeOH: CHCl 3 : NH 4 0H) gave 5.71 g of the title compound: MS (ES +) (MH +) 354.2. f) 1- (4-acetamido) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine To a stirred solution of the compound of Example 103 (e) (106.5 mg, 0.3 mmol) in CH 2 Cl 2 (1 ml) 4-acetamidobenzaldehyde (59.7 mg, 0.37 mmol) was added. The reaction was stirred for 2 hours and Na (OAc) 3 (140.0 mg, 0.66 mmol) was added. After stirring overnight, the reaction mixture was diluted with CHCl 3 (100 ml) and washed with 5% NaHCO 3 and brine, then dried (MgSO 4 ), filtered and concentrated. Column chromatography (silica gel, 5:95 MeOH: EtOAc) gave 105.1 mg of the title compound: MS (ES +) (MH +) 501.4. Example 104 Preparation of 1- (3-cyano) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared following the method of Example 103 (f) except using 3-cyanobenzaldehyde: MS (ES +) (MH +) 469.2. Example 105 Preparation of 1- (3-fluoro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using 3-fluorobenzaldehyde: MS (ES +) (MH +) 462.3. Example 106 Preparation of 1- (3-phenoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using 3-phenoxybenzaldehyde: MS (ES +) (MH <+>) 536.3. Example 107 Preparation of 1- (4-chloro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine Following the method of Example 103 (f) except using 4-chlorobenzaldehyde, the title compound was prepared: MS (ES +) (MH +) 478.3. Example 108 Preparation of 1- (4-trifluoromethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using 4- (trifluoromethyl) benzaldehyde: MS (ES +) (MH +) 512.3. Example 109 Preparation of 1- (3-trifluoromethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using 3- (trifluoromethyl) benzaldehyde: MS (ES +) (MH +) 512.2. Example 110 1- (4- (3- (N, N-dimethylamino) propoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine Manufacture The title compound was prepared according to the method of Example 103 (f) except using 4- (3-dimethylaminopropoxy) benzaldehyde: MS (ES +) (MH +) 545.2. Example 111 1- (4- (isopropyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using isopropylbenzaldehyde: MS (ES +) (MH +) 486.4. Example 112 Preparation of 1- (2-benzofuranyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine According to the method of Example 103 (f) except for using benzofuran-2-carboxaldehyde, the title compound was prepared: MS (ES +) (MH +) 484.2. Example 113 Preparation of 1- (2- (3-methylbenzo [b] thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using 3-methylbenzo [b] thiophene-2-carboxaldehyde: MS (ES +) (MH +) 514.2. Example 114 Preparation of 1- (2-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using the furan-2-carboxaldehyde: MS (ES +) (MH +) 434.1. Example 115 Preparation of 1- (3-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) but using furan-3-carboxaldehyde: MS (ES +) (MH +) 434.3. Example 116 Preparation of SB 1- (2-thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using thiophene-3-carboxaldehyde: MS (ES +) (MH +) 450.3. Example 117 Preparation of 1- (2-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using 2-nitrobenzaldehyde: MS (ES +) (MH +) 489.3. Example 118 Preparation of 1- (3-thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except using thiophene-2-carboxaldehyde: MS (ES +) (MH +) 450.2. Example 119 Preparation of 1- (3.4-dimethoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f), except using 3,4-dimethoxybenzaldehyde: MS (ES +) (MH +) 504.2. Example 120 Preparation of 1- (5-nitro-3-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine The title compound was prepared according to the method of Example 103 (f) except for using 5-nitrofuran-2-carboxaldehyde: MS (ES +) (MH +) 479.1. The above description and examples fully disclose methods for the preparation of the compounds of the invention and their uses. However, the invention is not limited to the specific embodiments described above, but includes all modifications thereof within the scope of the following claims. Various references to publications, patents, and other publications mentioned herein include the current state of the art, and are incorporated herein in their entirety by reference.
权利要求:
Claims (32) [1" claim-type="Currently amended] Compounds of formula (I) or pharmaceutically acceptable salts thereof. <Formula I> In the above formula, Y is Ar or NR 1 R 2 ; R 1 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O) or R "R'NC (S) ; R 2 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 3 is H, C 2-6 alkenyl, C 2-6 alkynyl, Het, Ar, or OR ', SR', NR ' 2 , N (R) C (O) OR ", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , C 1-6 alkyl optionally substituted by Het or Ar; R 4 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 5 is , Ar-C 0-6 alkyl, Het-C O-6 alkyl, adamantyl-C (O)-, Ar-C (0)-or Het-C (O)-; R 6 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O), R "R'NC (S) or R "OC (O) NR'CH (R * ) C (O); R 7 is C 3-6 cycloalkyl - C O-6 alkyl, Ar-C O-6 alkyl, Het-C O-6 alkyl, Ar-C O-6 alkoxy, Het-C O-6 alkoxy, or OR C, optionally substituted by ', SR ", NR' 2 , N (R ') C (O) OR", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , Het or Ar 1-6 alkyl; R * is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Each R ′ is independently H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "are each independently C 1-6 alkyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "'is H, C 1-6 alkyl, C 3-6 cycloalkyl -C 6 O-alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Z is C (O) or CH 2 ; n is 1, 2 or 3. [2" claim-type="Currently amended] A compound of formula (la) or a pharmaceutically acceptable salt thereof. <Formula Ia> In the above formula, R 1 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O) or R "R'NC (S) ; R 2 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 3 is H, C 2-6 alkenyl, C 2-6 alkynyl, Het, Ar, or OR ', SR', NR ' 2 , N (R) C (O) OR ", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , C 1-6 alkyl optionally substituted by Het or Ar; R 4 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 5 is , Ar-C 0-6 alkyl, Het-C O-6 alkyl, adamantyl-C (O)-, Ar-C (0)-or Het-C (O)-; R 6 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O), R "R'NC (S) or R "OC (O) NR'CH (R * ) C (O); R 7 is C 3-6 cycloalkyl - C O-6 alkyl, Ar-C O-6 alkyl, Het-C O-6 alkyl, Ar-C O-6 alkoxy, Het-C O-6 alkoxy, or OR C, optionally substituted by ', SR ", NR' 2 , N (R ') C (O) OR", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , Het or Ar 1-6 alkyl; R * is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, Het-C O-6 alkyl; Each R ′ is independently H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "are each independently C 1-6 alkyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "'is H, C 1-6 alkyl, C 3-6 cycloalkyl -C 6 O-alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Z is C (O) or CH 2 ; n is 1, 2 or 3. [3" claim-type="Currently amended] The compound of claim 1, wherein R 4 and R ″ ′ are each H. 3. [4" claim-type="Currently amended] The compound of claim 1, wherein R 3 is C 1-6 alkyl. [5" claim-type="Currently amended] The compound of claim 4, wherein R 3 is i-butyl. [6" claim-type="Currently amended] The compound of claim 1, wherein Y is NR 1 R 2 , R 2 is H, R 1 is R ″ C (O) or R ″ OC (O), wherein R ″ is C 1-6 alkyl, Ar— C 0-6 alkyl or Het-C 0-6 alkyl. [7" claim-type="Currently amended] The compound of claim 6, wherein R ″ in the R 1 group is tert-butyl, Phosphorus compounds. [8" claim-type="Currently amended] The compound of claim 1, wherein n is 1 or 2. [9" claim-type="Currently amended] The compound of claim 8, wherein n is 1. [10" claim-type="Currently amended] The compound of claim 1, wherein R 5 is benzyl or Wherein R 'is H, R 7 is C 1-6 alkyl, R 6 is R "OC (O) and Z is CH 2 . [11" claim-type="Currently amended] The compound of claim 10, wherein R 7 in R 5 is i-butyl and R ″ is benzyl. [12" claim-type="Currently amended] The compound of formula (Ib) according to claim 2. <Formula Ib> [13" claim-type="Currently amended] The compound of formula (Ic) according to claim 2. <Formula Ic> [14" claim-type="Currently amended] The method of claim 1, 3-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -pi Lollidine; 1-benzyl-3-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino]-pyrrolidine; 3-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl]- Pyrrolidine; 1-benzyl-3-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (benzyloxycarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucinyl] amino] -pyrrolidine; (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3R)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; 1-benzyl- (3R)-[[N α- (2-naphthyl) acetyl-L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3R)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3R)-[[N α- (3-quinolinecarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3R)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3R)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (2-naphthyl) acetyl-L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (3-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl-4-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -piperidine; 1-benzyl-4-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -piperidine; 1-benzyl-4-[[N α- (benzyloxycarbonyl) -L-leucineyl] amino] -piperidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3S)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (3-isoquinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- [3- (2-pyridyl) phenyl] -2-ethyl- (3R)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (1-adamantanecarbonyl)-(3R)-[[N α- (4-pyridylmethoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (1-adamantanecarbonyl)-(3S)-[[N α- (4-pyridylmethoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; (3R)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Carbonyl) amino] pentyl] -pyrrolidine; (3R)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3R)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3R)-[[N α- (benzothiazole-6-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine; (3R)-[[N α- (indol-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3R)-[[N α- (4-fluorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -Pyrrolidine; (3R)-[[N α- (4-methoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -Pyrrolidine; (3R)-[[N α- (3,4-dichlorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3R)-[[N α- (thiophen-2-carbonyl) -L-leucineyl] amino] -1-((2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3R)-[[N α- (4-biphenylcarbonyl) -L-leucineyl] amino] -1-((2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3R)-[[N α- (5-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbine Carbonyl) amino] pentyl] -pyrrolidine; (3R)-[[N α- (5-chlorobenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl ) Amino] pentyl] -pyrrolidine; (3R)-[[N α- (7-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Carbonyl) amino] pentyl] -pyrrolidine; (3R)-[[N α- (3-chlorobenzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[( Benzyloxycarbonyl) amino] pentyl] -pyrrolidine; (3R)-[[N α- (3- (2-pyridyl) benzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) Amino] pentyl] -pyrrolidine; (3S)-[[N α- (benzo [b] thiophene-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbine Carbonyl) amino] pentyl] -pyrrolidine; (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3S)-[[N α- (benzothiazole-6-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino ] Pentyl] -pyrrolidine; (3S)-[[N α- (indol-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3S)-[[N α- (4-fluorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -Pyrrolidine; (3S)-[[N α- (4-methoxybenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl] -Pyrrolidine; (3S)-[[N α- (3,4-dichlorobenzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3S)-[[N α- (thiophene-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] Pentyl] -pyrrolidine; (3S)-[[N α- (4-biphenylcarbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) amino] pentyl ] -Pyrrolidine; (3S)-[[N α- (5-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Carbonyl) amino] pentyl] -pyrrolidine; (3S)-[[N α- (5-chlorobenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl ) Amino] pentyl] -pyrrolidine; (3S)-[[N α- (7-methoxybenzofuran-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarb Carbonyl) amino] pentyl] -pyrrolidine; (3S)-[[N α- (3-chlorobenzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[( Benzyloxycarbonyl) amino] pentyl] -pyrrolidine; (3S)-[[N α- (3- (2-pyridyl) benzoyl) -L-leucineyl] amino] -1-[(2S) -4-methyl-2-[[(benzyloxycarbonyl) Amino] pentyl] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenyl) benzyl- (3S)-[[N α- (benzyloxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-phenyl) ethyl- (3S)-[[N α- (3-chlorobenzo [b] thiophen-2-carbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (2-quinolinecarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (benzofuran-2-carbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-phenoxy) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-fluoro) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-fluoro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-fluoro) benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-cyano) benzyl- (3S)-[[N α- (tert-butoxycarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-cyano) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (benzo [b] thiophen-2-carbonyl) -L-leucineyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (3,4-dimethoxybenzoyl) -L-leucinyl] amino] -pyrrolidine; 1-benzyl- (3S)-[[N α- (3- (2-dimethylaminoethoxy) -4-methoxybenzoyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4- (N, N-dimethylamino) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-methoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (4-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-carboxymethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3,4-methylenedioxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-naphthyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-Indolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-quinolinyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-quinolinyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (1-naphthyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-quinolinyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-pyrrolyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucinyl] amino] -pyrrolidine; 1- (3-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-pyridyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-acetamido) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-cyano) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-fluoro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-phenoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-chloro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4-Trifluoromethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-trifluoromethyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (4- (3- (N, N-dimethylamino) propoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine ; 1- (4- (isopropyl) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-benzofuranyl) methyl- (3S)-[[N α- (2-leucineyl) naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2- (3-methylbenzo [b] thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (2-nitro) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3-thiophenyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; 1- (3,4-dimethoxy) benzyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine; or 1- (5-Nitro-3-furanyl) methyl- (3S)-[[N α- (2-naphthylcarbonyl) -L-leucineyl] amino] -pyrrolidine Phosphorus compounds or pharmaceutically acceptable salts thereof. [15" claim-type="Currently amended] A pharmaceutical composition comprising the compound of any one of claims 1-14 and a pharmaceutically acceptable carrier. [16" claim-type="Currently amended] A method of inhibiting cysteine protease comprising administering the compound of claim 1. [17" claim-type="Currently amended] The method of claim 16, wherein the cysteine protease is cathepsin K. [18" claim-type="Currently amended] A method of inhibiting bone loss, comprising administering the compound of claim 1. [19" claim-type="Currently amended] A method of inhibiting osteoporosis comprising administering the compound of claim 1. [20" claim-type="Currently amended] A method of inhibiting gingival and periodontal disease comprising administering the compound of claim 1. [21" claim-type="Currently amended] A method of treating a disease characterized by excessive degradation of cartilage or matrix comprising administering the compound of claim 1. [22" claim-type="Currently amended] The method of claim 21, wherein the disease is deformable arthritis or rheumatoid arthritis. [23" claim-type="Currently amended] The compound according to any one of claims 1 to 14 for use as a medicament. [24" claim-type="Currently amended] Use of a compound of formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of a disease wherein the inhibition of cysteine protease is effective. [25" claim-type="Currently amended] The use of claim 24, wherein the cysteine protease is cathepsin K. [26" claim-type="Currently amended] Use of a compound of formula (I) as defined in claim 1 in the manufacture of a medicament for the inhibition of bone loss. [27" claim-type="Currently amended] Use of a compound of formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of osteoporosis. [28" claim-type="Currently amended] Use of a compound of formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of gingiva or periodontal disease. [29" claim-type="Currently amended] Use of a compound of formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of a disease characterized by excessive degradation of cartilage or matrix. [30" claim-type="Currently amended] The use of claim 29, wherein the disease characterized by excessive degradation of cartilage or matrix is osteoporosis or rheumatoid arthritis. [31" claim-type="Currently amended] Compounds of formula (II) or salts thereof in which reactive functional groups are protected (a) reacts with R ″ C (O) Cl; (b) react with R ″ C (O) OH in the presence of EDC and HOBT; (c) react with R ″ C (O) H and then reduce; (d) react with R ″ CO (O) Cl in the presence of a base; (e) after reacting with R ″ SO 2 Cl in the presence of a base, A process for preparing a compound of formula (I) as defined in claim 1 comprising removing any protecting group and optionally forming a pharmaceutically acceptable salt. <Formula II> Wherein R ″, R 3 , R 4 , R 5 and n are as defined in claim 1. [32" claim-type="Currently amended] A compound of formula (II) or a pharmaceutically acceptable salt thereof. <Formula II> In the above formula, R 3 is H, C 2-6 alkenyl, C 2-6 alkynyl, Het, Ar, or OR ', SR', NR ' 2 , N (R) C (O) OR ", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , C 1-6 alkyl optionally substituted by Het or Ar; R 4 is H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl or Het-C O-6 alkyl; R 5 is , Ar-C 0-6 alkyl, Het-C O-6 alkyl, adamantyl-C (O)-, Ar-C (0)-or Het-C (O)-; R 6 is R ", R" C (O), R "C (S), R" SO 2 , R "OC (O), R"R'NC (O), R "R'NC (S) or R "OC (O) NR'CH (R * ) C (O); R 7 is C 3-6 cycloalkyl - C O-6 alkyl, Ar-C O-6 alkyl, Het-C O-6 alkyl, Ar-C O-6 alkoxy, Het-C O-6 alkoxy, or OR C, optionally substituted by ', SR ", NR' 2 , N (R ') C (O) OR", C0 2 R', C0 2 NR ' 2 , N (C = NH) NH 2 , Het or Ar 1-6 alkyl; R * is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Each R ′ is independently H, C 1-6 alkyl, C 2-6 alkenyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "are each independently C 1-6 alkyl, C 3-6 cycloalkyl-O -C 6 - alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; R "'is H, C 1-6 alkyl, C 3-6 cycloalkyl -C 6 O-alkyl, Ar-C O-6 alkyl, or Het-C O-6 alkyl; Z is C (O) or CH 2 ; n is 1, 2 or 3.
类似技术:
公开号 | 公开日 | 专利标题 US10226459B2|2019-03-12|Aza spiro alkane derivatives as inhibitors of metalloproteases JP5518997B2|2014-06-11|Proline derivatives as cathepsin inhibitors DE60022508T2|2006-06-08|Inhibitors of serin proteases CA2081970C|1997-07-08|Hiv protease inhibitors useful for the treatment of aids JP5248783B2|2013-07-31|HCVNS-3 serine protease inhibitor RU2326117C2|2008-06-10|2,5-dioxoimidazolin-4-yl methylcarbonyl compounds, method of obtaining them, pharmaceutical mixtures containg them and thir use in medicine preparation US7169777B2|2007-01-30|Melanocortin receptor agonists US6653304B2|2003-11-25|Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases DE69819349T2|2004-07-22|1-amino-7-isochinoline derivatives as serine protease inhibitors KR100887038B1|2009-03-04|Derivatives of n-arylsulphonylbeta-amino acid comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical composition containing same US6555542B1|2003-04-29|Sulfonamide lactam inhibitors of FXa and method US6900196B2|2005-05-31|Serine protease inhibitors US6984648B2|2006-01-10|Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α CN102134230B|2019-06-28|Depeptidyl peptidase inhibitors US20170137412A1|2017-05-18|Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases CN100424082C|2008-10-08|4-| -quinolines as urotensin ii receptor antagonists US7157463B2|2007-01-02|Substituted piperidines/piperazines as melanocortin receptor agonists US6376665B1|2002-04-23|Amide derivatives as inhibitors of matrix metalloproteinases, TNF-α, and aggrecanase ES2201318T3|2004-03-16|Metaloprotease inhibitors of substituted cycline amines. TWI353977B|2011-12-11|Novel sulphonylpyrroles US6974836B2|2005-12-13|Diamines as modulators of chemokine receptor activity US6331542B1|2001-12-18|Protease inhibitors ES2246390T3|2006-02-16|Derivatives of piperazina as agonists of the receiver of melanocortina. JP5053960B2|2012-10-24|Compounds with growth hormone releasing properties US6180627B1|2001-01-30|Antithrombotic agents
同族专利:
公开号 | 公开日 US6369077B1|2002-04-09| EP0991753A1|2000-04-12| EP0991753A4|2001-07-11| CA2289010A1|1998-11-12| CO4950617A1|2000-09-01| AU7288598A|1998-11-27| HU0001285A3|2000-10-30| NO995433L|1999-11-05| ZA9803843B|1998-11-09| JP2001525809A|2001-12-11| PL336625A1|2000-07-03| BR9808502A|2000-05-23| CN1255162A|2000-05-31| IL131661D0|2001-01-28| NO995433D0|1999-11-05| MA26494A1|2004-12-20| HU0001285A2|2000-09-28| WO1998050534A1|1998-11-12| TR199902752T2|2000-06-21| PE73799A1|1999-10-22|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题
法律状态:
1997-05-08|Priority to US4686597P 1997-05-08|Priority to US60/046,865 1998-05-06|Application filed by 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스, 스미스클라인 비참 코포레이션 2001-02-15|Publication of KR20010012316A
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US4686597P| true| 1997-05-08|1997-05-08| US60/046,865|1997-05-08| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|